timestamp,url,text
2025-01-03 15:39:00+00:00,https://www.globenewswire.com/news-release/2025/01/03/3004072/28124/en/Big-Pharma-Partnering-Terms-and-Agreements-Analysis-Report-2024-with-Directory-of-Over-2-000-Deals-Signed-Since-2020.html,"Big Pharma Partnering Terms and Agreements Analysis Report 2024 with Directory of Over 2,000 Deals Signed Since 2020 The report provides a detailed analysis of over 2,000 Big Pharma deals signed since 2020, including trends, key players, deal financials, and contract details. It offers insights into how and why companies enter these partnerships."
2025-01-06 14:44:00+00:00,https://www.globenewswire.com/news-release/2025/01/06/3004746/28124/en/Ophthalmic-Lasers-Market-Forecast-Report-to-2029-Key-Trends-Include-Growing-Popularity-of-Femtosecond-Lasers-in-Ophthalmic-Surgery-and-Growing-Preference-for-Minimally-Invasive-Oph.html,"Ophthalmic Lasers Market Forecast Report to 2029: Key Trends Include Growing Popularity of Femtosecond Lasers in Ophthalmic Surgery and Growing Preference for Minimally Invasive Ophthalmic Procedures The global ophthalmic lasers market is expected to grow at a CAGR of 5.56% from 2023 to 2029, driven by the rising prevalence of eye disorders, advancements in laser technology, and the growing preference for minimally invasive procedures."
2025-01-07 12:00:00+00:00,https://www.globenewswire.com/news-release/2025/01/07/3005245/0/en/ONL-Therapeutics-Appoints-Penny-Fleck-as-Chief-Development-Officer.html,"ONL Therapeutics Appoints Penny Fleck as Chief Development Officer ONL Therapeutics, a clinical-stage biopharmaceutical company, has appointed Penny Fleck as its new Chief Development Officer. Fleck has over 20 years of experience leading R&D strategies at major pharmaceutical companies and will be responsible for advancing the company's lead asset, ONL1204 Ophthalmic Solution, towards a planned Phase 2 clinical study in geographic atrophy associated with age-related macular degeneration."
2025-01-08 08:56:00+00:00,https://www.globenewswire.com/news-release/2025/01/08/3005993/0/en/Brain-Ischemia-Market-grow-at-CAGR-of-7-6-Growth-Reaching-1-622-million-by-2032-Globally.html,"Brain Ischemia Market grow at CAGR of 7.6% Growth, Reaching $1,622 million by 2032 Globally The global brain ischemia market is expected to grow at a CAGR of 7.6% from 2024 to 2032, driven by the increasing prevalence of stroke and cardiovascular diseases, as well as technological advancements in medical devices and treatment options."
2025-01-08 09:15:00+00:00,https://www.fool.com/investing/2025/01/08/where-to-invest-100000-in-2025/?source=iedfolrf0000001,"Where to Invest $100,000 in 2025 The article provides investment recommendations for a $100,000 portfolio, suggesting a balanced approach with allocations to technology stocks, an S&P 500 index fund, individual stocks and ETFs, dividend stocks, and an opportunity fund."
2025-01-10 09:51:00+00:00,https://www.fool.com/investing/2025/01/10/2-dow-stocks-to-buy-hand-over-fist-2025-1-to-avoid/?source=iedfolrf0000001,"2 Dow Stocks to Buy Hand Over Fist in 2025 and 1 to Avoid The article discusses two Dow Jones Industrial Average stocks that are considered good buys for 2025 - Coca-Cola and Johnson & Johnson - due to their defensive business models, consistent cash flows, and attractive valuations. It also warns against investing in Nvidia, the newest Dow member, which may face headwinds from increased competition and a potential AI investment bubble."
2025-01-10 10:58:00+00:00,https://www.globenewswire.com/news-release/2025/01/10/3007486/28124/en/Nicotine-Replacement-Therapies-Market-Forecast-to-Reach-7-52-Billion-by-2032-Growing-Shift-Towards-Personalised-Nicotine-Replacement-Therapies.html,"Nicotine Replacement Therapies Market Forecast to Reach $7.52 Billion by 2032: Growing Shift Towards Personalised Nicotine Replacement Therapies The global nicotine replacement therapy market is expected to grow at a CAGR of 9.3% from 2024 to 2032, driven by rising health awareness, government initiatives, and technological advancements. Key players in the market include GSK, Pfizer, Johnson & Johnson, and others."
2025-01-10 13:30:00+00:00,https://www.investing.com/analysis/q4-earnings-season-preview-sp-500-stocks-poised-for-strongest-growth-in-3-years-200656072,"Q4 Earnings Season Preview: S&P 500 Stocks Poised for Strongest Growth in 3 Years The S&P 500 is expected to report its highest year-over-year earnings growth rate in three years in Q4 2024, led by the Financials, Communication Services, and Information Technology sectors. However, the Energy sector is forecast to see a significant decline in earnings."
2025-01-13 09:46:00+00:00,https://www.globenewswire.com/news-release/2025/01/13/3008183/28124/en/Ophthalmic-Drugs-Global-Market-Report-2025-Innovations-in-Retinal-Disorders-Glaucoma-Drive-Global-Ophthalmic-Medicines-Surge.html,"Ophthalmic Drugs Global Market Report 2025: Innovations in Retinal Disorders, Glaucoma Drive Global Ophthalmic Medicines Surge The global ophthalmic drugs market is expected to surpass $35 billion in 2025, driven by rising incidences of eye-related conditions and a strong pipeline of new drugs. However, side effects of topical ophthalmic drugs may limit market growth, necessitating a comprehensive strategy to address safety concerns."
2025-01-13 10:05:00+00:00,https://www.fool.com/investing/2025/01/13/9-dividend-etfs-to-buy-with-200-and-hold-forever/?source=iedfolrf0000001,"9 Dividend ETFs to Buy With $200 and Hold Forever Dividends are powerful wealth builders, and investing in dividend-paying stocks or exchange-traded funds (ETFs) can be an effective way to grow your portfolio over time. The article provides examples of dividend-paying companies and ETFs, and discusses the benefits of dividend investing."
2025-01-13 11:09:00+00:00,https://www.fool.com/investing/2025/01/13/2-beaten-down-dividend-stocks-to-buy-in-2025/?source=iedfolrf0000001,"2 Beaten-Down Dividend Stocks to Buy in 2025 CVS Health and Johnson & Johnson are attractive dividend stocks despite facing some headwinds. CVS Health's long-term strategy and strong dividend program make it a solid income stock, while Johnson & Johnson's stability, adaptability, and secure dividend make it an excellent pick for income-seeking investors."
2025-01-13 15:03:27+00:00,https://www.benzinga.com/general/biotech/25/01/42948170/like-bristol-myers-squibb-and-abbvie-johnson-johnson-seeks-to-bolster-neuropsychiatric-portfolio-,"Like Bristol-Myers Squibb And AbbVie, Johnson & Johnson Seeks To Bolster Neuropsychiatric Portfolio With $15 Billion Deal Johnson & Johnson agreed to acquire Intra-Cellular Therapies for $14.6 billion, adding the company's central nervous system-focused therapies, including the approved drug Caplyta, to its portfolio."
2025-01-14 18:00:00+00:00,https://www.globenewswire.com/news-release/2025/01/14/3009572/0/en/Evolving-Landscape-of-Cardiology-Segment-Key-Market-Insights-of-Latest-Published-Rare-Cardiovascular-Diseases-Report-Giant-Cell-Arteritis-Pulmonary-Arterial-Hypertension-and-Restri.html,"Evolving Landscape of Cardiology Segment: Key Market Insights of Latest Published Rare Cardiovascular Diseases Report â€” Giant-Cell Arteritis, Pulmonary Arterial Hypertension, and Restrictive Cardiomyopathy | DelveInsight The article discusses the evolving landscape of rare cardiovascular diseases, including Giant-Cell Arteritis, Pulmonary Arterial Hypertension, and Restrictive Cardiomyopathy. It highlights the challenges in diagnosis and treatment, as well as the growing market size and pipeline of new therapies for these conditions."
2025-01-15 10:10:00+00:00,https://www.fool.com/investing/2025/01/15/got-200-2-dividend-stocks-to-buy-and-hold-forever/?source=iedfolrf0000001,"Got $200? 2 Dividend Stocks to Buy and Hold Forever Pfizer and Johnson & Johnson are two pharmaceutical industry stalwarts with long histories, generous dividends, and solid growth prospects. Despite recent challenges, Pfizer is reinventing itself with a focus on oncology, while Johnson & Johnson's diversification and consistent dividend growth make it a timeless investment option."
2025-01-16 12:00:00+00:00,https://www.globenewswire.com/news-release/2025/01/16/3010667/0/en/Surgical-Gown-Market-is-Set-to-Grow-at-a-5-4-CAGR-Projected-to-Reach-US-2-734-7-Million-by-2034-Fact-MR-Report.html,"Surgical Gown Market is Set to Grow at a 5.4% CAGR, Projected to Reach US$ 2,734.7 Million by 2034 | Fact.MR Report The global surgical gown market is expected to grow at a 5.4% CAGR, reaching US$ 2,734.7 million by 2034. The demand for surgical gowns has increased significantly due to the COVID-19 pandemic, with the production of personal protective equipment also rising to meet the growing need."
2025-01-17 08:30:00+00:00,https://www.globenewswire.com/news-release/2025/01/17/3011258/0/en/Global-Pharma-Biotech-CRM-Software-Market-To-Surpass-Valuation-of-US-20-0-Billion-by-2033-Astute-Analytica.html,"Global Pharma & Biotech CRM Software Market To Surpass Valuation of US$ 20.0 Billion by 2033 | Astute Analytica The global pharma & biotech CRM software market is projected to reach US$ 20.0 billion by 2033, driven by rapid advancements in technology and heightened regulatory requirements. Adoption of AI-driven CRM solutions and cloud-based platforms are key trends in the industry."
2025-01-17 09:53:00+00:00,https://www.globenewswire.com/news-release/2025/01/17/3011290/28124/en/7MM-Type-1-Diabetes-Market-Drug-Forecast-and-Market-Analysis-2023-2024-2033-Value-to-Reach-9-91-Billion-Synergistic-Rise-of-Pumps-CGMs-and-Ultra-rapid-acting-Insulins-in-T1D-Manage.html,"7MM Type 1 Diabetes Market Drug Forecast and Market Analysis 2023-2024 & 2033: Value to Reach $9.91 Billion - Synergistic Rise of Pumps, CGMs, and Ultra-rapid-acting Insulins in T1D Management The type 1 diabetes (T1D) market is expected to grow at a strong CAGR of 13.3% from 2023 to 2033, reaching $9.91 billion. Key drivers include the increased use of rapid-acting insulins, insulin pumps, and immunomodulatory therapies, as well as the rising global prevalence of T1D. However, high prices, patent expiries, and the failure of disease-modifying therapies in clinical trials pose challenges to market growth."
2025-01-17 11:00:00+00:00,https://www.globenewswire.com/news-release/2025/01/17/3011318/0/en/Enovis-Announces-Leadership-Change-to-International-Surgical-Business.html,"Enovisâ„¢ Announces Leadership Change to International Surgical Business Enovis, a global medical technology company, announced that Davide Visentin will succeed Dr. Benjamin Reinmann as President of Enovis International Surgical, effective March 1, 2025. Visentin is an experienced MedTech executive who previously held leadership roles at BD, Stryker, and Johnson & Johnson Depuy Synthes."
2025-01-17 13:45:00+00:00,https://www.fool.com/investing/2025/01/17/buy-vanguard-dividend-passive-income-growth-stock/?source=iedfolrf0000001,"This Vanguard ETF Has 23% of Its Portfolio Invested in Tech Stocks, but It Can Still Help You Generate Decades of Passive Income The Vanguard Dividend Appreciation ETF (VIG) offers a balanced portfolio of quality businesses with a runway for earnings and dividend growth, providing a passive way to invest in the stock market."
2025-01-18 11:18:00+00:00,https://www.fool.com/investing/2025/01/18/3-super-safe-dividend-stocks-to-buy-for-2025-and-b/?source=iedfolrf0000001,"3 Super-Safe Dividend Stocks to Buy for 2025 and Beyond The article highlights three companies with strong financial profiles and stable dividends: Johnson & Johnson, ExxonMobil, and Realty Income. These companies are expected to continue increasing their dividends due to their robust cash flows, low debt levels, and growth prospects."
2025-01-20 10:53:00+00:00,https://www.globenewswire.com/news-release/2025/01/20/3011957/28124/en/Top-10-Medical-Device-Predictions-for-2025.html,"Top 10 Medical Device Predictions for 2025 The report identifies the top 10 themes that will impact the medical devices industry in 2025, including artificial intelligence, regulation, and the US-China trade war. It provides predictions, identifies winners and losers, and points to further reading for each theme."
2025-01-20 14:55:00+00:00,https://www.globenewswire.com/news-release/2025/01/20/3012153/0/en/Pain-Management-Therapeutics-Market-Is-Expected-To-Reach-Revenue-Of-USD-120-7-Bn-By-2033-At-3-9-CAGR-Dimension-Market-Research.html,"Pain Management Therapeutics Market Is Expected To Reach Revenue Of USD 120.7 Bn By 2033, At 3.9% CAGR: Dimension Market Research. The global pain management therapeutics market is expected to grow from $85.2 billion in 2024 to $120.7 billion by 2033, driven by the increasing prevalence of chronic pain conditions and the development of non-opioid therapies."
2025-01-20 15:45:00+00:00,https://www.globenewswire.com/news-release/2025/01/20/3012178/32656/en/Baby-Skincare-Market-Set-to-Grow-6-1-Annually-Driven-by-Surging-Demand-for-Organic-and-Chemical-Free-Products-by-2034-Latest-Insights-by-TMR.html,"Baby Skincare Market Set to Grow 6.1% Annually, Driven by Surging Demand for Organic and Chemical-Free Products by 2034 | Latest Insights by TMR The global baby skincare market is expected to grow at a CAGR of 6.1% from 2024 to 2034, driven by increasing awareness of infant skin health, preference for organic and chemical-free products, and the rise of e-commerce platforms."
2025-01-21 09:17:00+00:00,https://www.fool.com/investing/2025/01/21/3-unstoppable-dividend-growth-stocks-yielding-more/?source=iedfolrf0000001,"3 Unstoppable Dividend-Growth Stocks Yielding More Than 3% That Income-Seeking Investors Want to Buy in 2025 and Hold Forever The article highlights three healthcare stocks - AbbVie, Johnson & Johnson, and Medtronic - that offer high dividend yields and consistent dividend growth, making them attractive for income-seeking investors."
2025-01-21 10:00:00+00:00,https://www.globenewswire.com/news-release/2025/01/21/3012425/0/en/Antiseptics-and-Disinfectants-Market-Size-to-Worth-USD-100-89-billion-by-2033-at-a-CAGR-of-9-5-Straits-Research.html,"Antiseptics and Disinfectants Market Size to Worth USD 100.89 billion by 2033, at a CAGR of 9.5% | Straits Research The global antiseptics and disinfectants market is expected to grow from $48.81 billion in 2025 to $100.89 billion by 2033, driven by the increasing prevalence of hospital-acquired infections and the growing use of endoscope reprocessors and surgical units."
2025-01-21 10:34:00+00:00,https://www.fool.com/investing/2025/01/21/buy-2024-worst-performing-dow-jones-stocks-2025/?source=iedfolrf0000001,"Can the 8 Worst-Performing Dow Jones Stocks in 2024 Beat the S&P 500 in 2025? The article discusses several Dow Jones stocks that could be good buys in 2025, including Boeing, Nike, Johnson & Johnson, Merck, Amgen, UnitedHealth, Chevron, and McDonald's. It analyzes the current state and future prospects of these companies, highlighting their dividend yields and growth potential."
2025-01-22 13:21:09+00:00,https://www.benzinga.com/25/01/43125966/johnson-johnson-reports-q4-earnings-above-wall-street-estimates-driven-by-strong-cancer-drugs-revenue,"Johnson & Johnson Q4 Earnings: Cancer Drugs Performance Drives Revenue Beat, Issues Strong FY25 Outlook Johnson & Johnson reported strong Q4 earnings, driven by the performance of its cancer drugs. The company also issued a positive outlook for fiscal year 2025, with expected sales of $90.9 billion to $91.7 billion and adjusted EPS of $10.75 to $10.95."
2025-01-22 13:44:39+00:00,https://www.fool.com/data-news/2025/01/22/johnson-johnson-tops-eps-forecasts/?source=iedfolrf0000001,"Johnson & Johnson Tops Q4 EPS Forecasts Johnson & Johnson reported strong fourth-quarter 2024 results, with revenue and adjusted earnings per share exceeding analyst estimates. However, the company faces challenges due to patent expirations and regulatory hurdles, which have affected its financial performance."
2025-01-22 14:00:00+00:00,https://www.globenewswire.com/news-release/2025/01/22/3013519/0/en/Model-N-Celebrates-25-Years-of-Revenue-Optimization-and-Compliance-Leadership-and-Launches-Registration-for-Rainmaker-Industry-Event.html,"Model N Celebrates 25 Years of Revenue Optimization and Compliance Leadership and Launches Registration for Rainmaker Industry Event Model N, a leader in revenue optimization and compliance solutions for life sciences and high-tech companies, is celebrating its 25th anniversary and launching registration for its annual Rainmaker conference. The event will showcase the company's latest innovations in revenue management technology, with a focus on AI, data analytics, and user experience."
2025-01-23 09:54:00+00:00,https://www.globenewswire.com/news-release/2025/01/23/3014059/28124/en/Wearable-Artificial-Organs-Global-Market-Research-2023-2024-Forecasts-to-2034-Government-Funding-and-Initiatives-Patient-Preference-for-Non-Invasive-Solutions-Boost-Growth.html,"Wearable Artificial Organs Global Market Research 2023-2024 & Forecasts to 2034: Government Funding and Initiatives, & Patient Preference for Non-Invasive Solutions Boost Growth The global wearable artificial organs market is expected to grow significantly from $11.17 billion in 2024 to $64.19 billion by 2035, driven by government initiatives, technological advancements, and patient preference for non-invasive solutions. North America and Asia Pacific are expected to be the key growth regions."
2025-01-23 10:08:00+00:00,https://www.fool.com/investing/2025/01/23/this-is-1-of-the-healthiest-high-yielding-dividend/?source=iedfolrf0000001,"This Is 1 of the Healthiest High-Yielding Dividend Stocks You'll Find Johnson & Johnson is an elite dividend stock with a 62-year history of dividend increases, a high yield of around 3.4%, and a fortress balance sheet with an AAA credit rating. The company's heavy investments in R&D and acquisitions position it for future growth, supporting its ability to continue increasing its dividend at a healthy rate."
2025-01-23 10:45:00+00:00,https://www.globenewswire.com/news-release/2025/01/23/3014089/0/en/Findings-from-pivotal-nipocalimab-Phase-3-study-in-a-broad-antibody-positive-population-of-people-living-with-generalised-myasthenia-gravis-published-in-The-Lancet-Neurology.html,"Findings from pivotal nipocalimab Phase 3 study in a broad antibody positive population of people living with generalised myasthenia gravis published in The Lancet Neurology Nipocalimab, an investigational FcRn blocker, demonstrated sustained disease control over 24 weeks in a broad population of antibody positive adults with generalized myasthenia gravis (gMG). The Phase 3 Vivacity-MG3 study met its primary endpoint, showing statistically significant and clinically meaningful improvement in the MG-ADL score."
2025-01-23 14:09:00+00:00,https://www.investing.com/analysis/1-dividend-stalwart-to-buy-1-to-sell-post-earnings-200656541,"1 Dividend Stalwart to Buy, 1 to Sell Post Earnings Johnson & Johnson faces investor concerns due to weaker revenue forecasts and ongoing legal challenges, while Procter & Gamble maintained steady guidance and saw optimism from investors."
2025-01-23 20:02:29+00:00,https://www.benzinga.com/general/biotech/25/01/43174150/johnson-johnsons-medtech-momentum-expected-to-rebound-in-2025-despite-current-hurdles-analyst,Johnson & Johnson's MedTech Momentum Expected To Rebound In 2025 Despite Current Hurdles: Analyst Johnson & Johnson's MedTech segment is expected to rebound in 2025 despite facing challenges like Stelara exclusivity loss and increased competition. Analysts maintain a neutral to positive outlook on the company's prospects.
2025-01-23 21:57:00+00:00,https://www.fool.com/investing/2025/01/23/up-about-62-in-a-year-can-intuitive-surgical-stock/?source=iedfolrf0000001,"Up About 62% in a Year, Can Intuitive Surgical Stock Keep Soaring? Intuitive Surgical's da Vinci 5 surgical robot system is gaining traction, with hospitals worldwide placing 493 systems in the third quarter of 2024. The new system offers advanced features and integration, giving Intuitive Surgical a lead over competitors like Johnson & Johnson's Ottava system. However, Intuitive Surgical's stock is trading at a high valuation, and investors should be cautious about potential risks."
2025-01-24 00:30:00+00:00,https://www.globenewswire.com/news-release/2025/01/24/3014679/0/en/Hip-and-Knee-Reconstructive-Market-to-Reach-USD-41-071-4-Million-by-2035-Growing-at-a-5-6-CAGR-from-2025-to-2035-FMI.html,"Hip and Knee Reconstructive Market to Reach USD 41,071.4 Million by 2035, Growing at a 5.6% CAGR from 2025 to 2035 | FMI The hip and knee reconstructive market is expected to grow significantly from 2025 to 2035, driven by technological advancements, an aging population, and the rising prevalence of orthopedic disorders. The market is projected to reach USD 41,071.4 million by 2035, with a CAGR of 5.6%."
2025-01-24 09:51:00+00:00,https://www.fool.com/investing/2025/01/24/5-safest-high-yield-dividend-stocks-buy-for-2025/?source=iedfolrf0000001,"5 of the Safest High-Yield Dividend Stocks You Can Confidently Buy for 2025 The article highlights five high-yield dividend stocks that are considered safe investments for 2025, including Enterprise Products Partners, Coca-Cola, Realty Income, York Water, and Johnson & Johnson. These companies are praised for their consistent dividend payments, predictable cash flows, and ability to navigate economic downturns."
2025-01-25 11:17:00+00:00,https://www.fool.com/investing/2025/01/25/these-were-the-5-worst-performing-stocks-in-the-do/?source=iedfolrf0000001,"These Were the 5 Worst-Performing Stocks in the Dow Jones Industrial Average in 2024 The Dow Jones Industrial Average gained 14% in 2024, but five stocks - Johnson & Johnson, Merck, Amgen, Nike, and Boeing - were the worst performers, all losing value over the year. The reasons for their underperformance vary, from pandemic-related issues to market share declines and CEO changes."
2025-01-26 12:57:00+00:00,https://www.fool.com/investing/2025/01/26/prediction-this-company-will-have-trillion-dollar/?source=iedfolrf0000001,"Prediction: This Company Will Have a Trillion-Dollar Market Cap by 2040 Intuitive Surgical, a leading provider of robotic-assisted surgical equipment, has the potential to become a trillion-dollar company by 2040 due to its strong market position, high switching costs, and continued innovation. The article discusses the company's growth prospects, competitive landscape, and the benefits of robotic-assisted surgeries."
2025-01-27 15:55:00+00:00,https://www.globenewswire.com/news-release/2025/01/27/3015782/0/en/Alopecia-Treatment-Market-Size-to-Surpass-USD-5-20-Billion-by-2033-Straits-Research.html,"Alopecia Treatment Market Size to Surpass USDÂ 5.20 Billion by 2033 | Straits Research The global alopecia treatment market is expected to grow from $3.62 billion in 2025 to $5.20 billion by 2033, driven by the surge in the geriatric population and growth opportunities in emerging markets."
2025-01-31 18:52:00+00:00,https://www.globenewswire.com/news-release/2025/01/31/3018975/0/en/FDA-Approval-of-Eli-Lilly-s-Omvoh-for-Crohn-s-Disease-Adds-a-New-Option-but-Uptake-May-be-Hampered-by-US-Gastroenterologists-Brand-Preferences-Among-the-IL-23-Class-According-to-Sp.html,"FDA Approval of Eli Lillyâ€™s Omvoh for Crohnâ€™s Disease Adds a New Option, but Uptake May be Hampered by US Gastroenterologistsâ€™ Brand Preferences Among the IL-23 Class, According to Spherix Global Insights The FDA has approved Eli Lilly's Omvoh for Crohn's disease, but its uptake may be hampered by gastroenterologists' preference for Johnson & Johnson's Tremfya among the IL-23 class of treatments."
2025-02-01 11:14:00+00:00,https://www.fool.com/investing/2025/02/01/did-johnson-johnson-just-give-investors-23-billion/?source=iedfolrf0000001,"Did Johnson & Johnson Just Give Investors 23 Billion Reasons to Buy Its Stock? Johnson & Johnson reported strong Q4 2024 earnings, with top-line growth and a double beat on analyst estimates. The company's outlook for 2025 is also positive, with guidance for improved profitability and continued dividend growth. The article suggests that Johnson & Johnson's stock is a buy due to its growth potential and reliable income stream."
2025-02-01 12:30:00+00:00,https://www.fool.com/investing/2025/02/01/johnson-johnson-announces-a-major-acquisition-can/?source=iedfolrf0000001,"Johnson & Johnson Announces a Major Acquisition. Can It Turn the Stock's Fortunes Around? Johnson & Johnson announced plans to acquire Intra-Cellular Therapies for $14.6 billion, which could bolster its pipeline and strengthen its neurological business. However, the acquisition is unlikely to turn Johnson & Johnson into a high-growth stock, as its growth rate is expected to remain in the single digits."
2025-02-02 17:21:00+00:00,https://www.fool.com/investing/2025/02/02/is-johnson-johnson-stock-a-buy/?source=iedfolrf0000001,"Is Johnson & Johnson Stock a Buy? Johnson & Johnson is a healthcare giant with a diverse portfolio of pharmaceutical products and medical devices. While it has faced legal and regulatory headwinds, the company's financial results remain solid, and it has growth opportunities in areas like robotic-assisted surgery. The stock may be a good choice for long-term, income-seeking investors, despite some challenges."
2025-02-04 14:00:00+00:00,https://www.globenewswire.com/news-release/2025/02/04/3020375/0/en/Ninety-Nine-Percent-of-Life-Sciences-and-High-Tech-Leaders-Expect-AI-to-Drive-Revenue-Management-Value-in-2025.html,"Ninety-Nine Percent of Life Sciences and High-Tech Leaders Expect AI to Drive Revenue Management Value in 2025 The report reveals that life sciences and high-tech companies are increasingly adopting AI and automation to optimize their revenue operations, with 62% using or planning to implement generative AI. Pharmaceutical companies are focused on regulatory readiness, while high-tech manufacturers are strengthening channel intelligence."
2025-02-06 09:51:00+00:00,https://www.globenewswire.com/news-release/2025/02/06/3021793/28124/en/Respiratory-Disease-Vaccines-Market-Research-Report-2025-Analysis-and-Forecast-2020-2030-Featuring-GSK-Johnson-Johnson-Services-Pfizer-Sanofi-Serum-Institute-of-India-SINOVAC-Biote.html,"Respiratory Disease Vaccines Market Research Report 2025: Analysis and Forecast (2020-2030) Featuring GSK, Johnson & Johnson Services, Pfizer, Sanofi, Serum Institute of India, SINOVAC Biotech & More The global respiratory disease vaccine market is expected to grow from $94.6 billion in 2024 to $101.56 billion by 2030, driven by factors such as the increasing prevalence of respiratory diseases, the aging population, and government vaccine mandates and recommendations."
2025-02-06 09:53:00+00:00,https://www.globenewswire.com/news-release/2025/02/06/3021794/28124/en/Mineral-Sunscreen-Market-Industry-Analysis-Trends-and-Forecasts-The-Market-is-Expected-to-Expand-at-a-CAGR-of-5-30-Reaching-USD-1-77-Billion-in-2025-and-USD-2-55-Billion-by-2032.html,"Mineral Sunscreen Market Industry Analysis, Trends and Forecasts: The Market is Expected to Expand at a CAGR of 5.30%, Reaching USD 1.77 Billion in 2025 and USD 2.55 Billion by 2032 The global mineral sunscreen market is expected to grow at a CAGR of 5.30%, driven by increasing consumer awareness of the harmful effects of UV radiation and a shift towards natural and organic skincare solutions. Key players are focusing on innovation, product expansion, and strategic partnerships to maintain a competitive edge."
2025-02-07 16:39:00+00:00,https://www.globenewswire.com/news-release/2025/02/07/3022898/32656/en/Paresthesia-Treatment-Market-Outlook-USD-8-0-Billion-by-2034-Growing-with-an-Aging-Population-and-Rising-Healthcare-Expenditures-Analysis-by-TMR.html,"Paresthesia Treatment Market Outlook: USD 8.0 Billion by 2034, Growing with an Aging Population and Rising Healthcare Expenditures | Analysis by TMR The global paresthesia treatment market is expected to grow to $8.0 billion by 2034, driven by the increasing prevalence of neurological disorders, advancements in medical technology, and rising healthcare expenditures."
2025-02-08 09:40:00+00:00,https://www.fool.com/investing/2025/02/08/should-buy-highest-paying-dividend-stock-dow/?source=iedfolrf0000001,"Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones? The article analyzes the top dividend-paying stocks in the Dow Jones Industrial Average, including Verizon, Chevron, and Johnson & Johnson. It discusses the growth prospects, debt levels, and dividend yields of these companies, providing insights for investors."
2025-02-09 12:15:00+00:00,https://www.fool.com/investing/2025/02/09/2-stocks-to-buy-if-there-is-a-market-crash-in-2025/?source=iedfolrf0000001,"2 Stocks to Buy if There Is a Market Crash in 2025 The article discusses investing in defensive stocks like Johnson & Johnson and HCA Healthcare that can withstand market downturns. It highlights their resilient businesses in the healthcare industry, which is less affected by economic conditions."
2025-02-10 10:30:00+00:00,https://www.globenewswire.com/news-release/2025/02/10/3023249/0/en/Mouth-Freshener-Market-to-Reach-USD-36-33-Billion-by-2035-Key-Trends-Emerging-Opportunities-and-Competitive-Outlook-FMI.html,"Mouth Freshener Market to Reach USD 36.33 Billion by 2035 â€“ Key Trends, Emerging Opportunities, and Competitive Outlook | FMI The global mouth freshener market is expected to reach USD 36.33 billion by 2035, growing at a CAGR of 6.7% from 2025 to 2035. The rising demand is driven by increased consumer awareness of oral hygiene and the growing use of tobacco and alcohol."
2025-02-10 14:00:00+00:00,https://www.globenewswire.com/news-release/2025/02/10/3023467/0/en/Wound-Closure-Market-Size-to-Hit-USD-26-63-Billion-by-2032-Growing-at-a-CAGR-of-6-47-SNS-Insider.html,"Wound Closure Market Size to Hit USD 26.63 Billion by 2032, Growing at a CAGR of 6.47% - SNS Insider The global Wound Closure Market is expected to grow from $15.17 billion in 2023 to $26.63 billion by 2032, driven by increasing chronic wounds, aging population, and rising healthcare infrastructure. Sutures and hemostatic agents are the key product types, with general surgery and cardiology being the major application areas."
2025-02-10 15:00:00+00:00,https://www.globenewswire.com/news-release/2025/02/10/3023550/0/en/Dry-Eye-Treatment-Devices-Market-Poised-to-Attain-Valuation-of-US-898-78-Million-By-2033-Pharmacological-Synergy-Driving-Demand-for-Advanced-Dry-Eye-Treatment-Devices-Says-Astute-A.html,"Dry Eye Treatment Devices Market Poised to Attain Valuation of US$ 898.78 Million By 2033 | Pharmacological Synergy Driving Demand for Advanced Dry Eye Treatment Devices Says Astute Analytica The global dry eye treatment devices market is expected to reach $898.78 million by 2033, driven by the increasing prevalence of dry eye disease and the development of innovative treatment options. The market is seeing a shift towards more sophisticated devices that offer targeted therapies, such as the LipiFlow System and iLux Device for treating meibomian gland dysfunction, and the trueTear intranasal neurostimulation device for stimulating tear production."
2025-02-10 15:00:00+00:00,https://www.globenewswire.com/news-release/2025/02/10/3023557/0/en/Digital-PCR-Market-Size-Expected-to-Reach-USD-17-45-Bn-by-2034.html,"Digital PCR Market Size Expected to Reach USD 17.45 Bn by 2034 The global digital PCR market is expected to grow from $7.82 billion in 2025 to $17.45 billion by 2034, driven by factors such as the launch of new products, increased acquisitions, and the rising incidence of infectious diseases, cancer, and genetic disorders."
2025-02-12 12:11:57+00:00,https://www.benzinga.com/general/biotech/25/02/43653157/johnson-johnson-explores-sale-of-stroke-device-maker-cerenovus-as-medtech-overhaul-accelerates,"Johnson & Johnson Explores Sale of Stroke Device Maker Cerenovus As MedTech Overhaul Accelerates Johnson & Johnson is considering selling its stroke care unit Cerenovus, which could fetch over $1 billion, as part of its efforts to streamline its medical technology division following a series of acquisitions."
2025-02-12 13:01:00+00:00,https://www.globenewswire.com/news-release/2025/02/12/3025013/28124/en/Lotion-in-Motion-Trends-Driving-the-190-Billion-Body-Lotions-Industry-Forward-2025-2030.html,"Lotion in Motion: Trends Driving the $190+ Billion Body Lotions Industry Forward, 2025-2030 The global body lotions market is expected to grow from $107.5 billion in 2024 to $190.9 billion by 2030, driven by increasing consumer awareness of skincare health, the rising prevalence of dry skin conditions, and the growing demand for multifunctional skincare products."
2025-02-13 13:30:58+00:00,https://www.benzinga.com/general/biotech/25/02/43692253/sanofi-johnson-johnson-partnered-vaccine-against-bacterial-sepsis-flunks-late-stage-study,"Sanofi/Johnson & Johnson Partnered Vaccine Against Bacterial Sepsis Flunks Late-Stage Study Sanofi and Johnson & Johnson have discontinued the phase 3 study of their vaccine candidate for extraintestinal pathogenic E. coli after it showed insufficient efficacy in preventing invasive E. coli disease. As a result, Sanofi has recorded a $250 million impairment charge, which negatively impacts its Q4 2024 IFRS EPS."
2025-02-13 14:00:00+00:00,https://www.globenewswire.com/news-release/2025/02/13/3025919/0/en/Respiratory-Syncytial-Virus-Therapeutics-Market-to-Hit-USD-4-64-Billion-by-2032-Growing-at-a-14-5-CAGR-SNS-Insider.html,"Respiratory Syncytial Virus Therapeutics Market to Hit USD 4.64 Billion by 2032, Growing at a 14.5% CAGR â€“ SNS Insider The global Respiratory Syncytial Virus (RSV) Therapeutics market is expected to grow significantly, driven by increased awareness of RSV's health risks and the development of advanced treatment options. Key players in the market include Moderna, Pfizer, GlaxoSmithKline, AstraZeneca, Sanofi, Merck, Johnson & Johnson, Novavax, Bavarian Nordic, and Alnylam Pharmaceuticals."
2025-02-20 08:30:00+00:00,https://www.globenewswire.com/news-release/2025/02/20/3029340/0/en/Global-Magnetic-Ablation-Catheters-Market-Poised-for-Significant-Growth-Projected-to-Reach-USD-1-114-4-Million-by-2035-Driven-by-Technological-Advancements-and-Rising-Cardiovascula.html,"Global Magnetic Ablation Catheters Market Poised for Significant Growth, Projected to Reach USD 1,114.4 Million by 2035 Driven by Technological Advancements and Rising Cardiovascular Cases | Future Market Insights, Inc. The global magnetic ablation catheters market is expected to grow significantly, reaching $1.1 billion by 2035, driven by advancements in technology and the rising prevalence of cardiovascular diseases. Key factors driving growth include the increasing adoption of minimally invasive procedures and continued investment in healthcare infrastructure and R&D."
2025-02-20 11:00:00+00:00,https://www.globenewswire.com/news-release/2025/02/20/3029397/0/en/Surgical-Sutures-Market-to-Reach-8-8-billion-by-2032-at-6-8-CAGR-Allied-Market-Research.html,"Surgical Sutures Market to Reach $8.8 billion, by 2032 at 6.8% CAGR: Allied Market Research The surgical sutures market is expected to grow from $4.9 billion in 2023 to $8.8 billion by 2032, driven by the rising number of surgeries, increasing adoption of advanced sutures, and the growing demand for minimally invasive procedures."
2025-02-20 18:00:00+00:00,https://www.globenewswire.com/news-release/2025/02/20/3029945/0/en/Antibody-Drug-Conjugates-Market-to-Witness-Rapid-Growth-Across-7MM-During-the-Study-Period-2020-2034-as-New-Innovations-Drive-Therapy-Advancements-DelveInsight.html,"Antibody-Drug Conjugates Market to Witness Rapid Growth Across 7MM During the Study Period (2020â€“2034) as New Innovations Drive Therapy Advancements | DelveInsight The antibody-drug conjugates market is expected to grow significantly in the 7MM by 2034, driven by advances in targeted therapies and ongoing research to enhance the effectiveness and safety of these treatments."
2025-02-21 08:25:00+00:00,https://www.fool.com/investing/2025/02/21/buy-ultra-safe-high-yield-dividend-king-stock/?source=iedfolrf0000001,"Buy This Ultra-Safe High-Yield Dividend King Stock for Reliable Passive Income Kenvue, a consumer health company spun off from Johnson & Johnson, has faced criticism from activist investors but is working to improve its cost efficiency and marketing efforts. Despite a near-term outlook of flat sales, the company's strong portfolio of brands and growing dividend make it a solid income stock for patient investors."
2025-02-21 09:41:00+00:00,https://www.globenewswire.com/news-release/2025/02/21/3030283/28124/en/3-77-Bn-Surgical-Meshes-Market-Opportunities-and-Strategies-to-2034-Medtronic-Leads-the-Fragmented-Market-Followed-by-Boston-Scientific-and-Johnson-Johnson.html,"$3.77 Bn Surgical Meshes Market Opportunities and Strategies to 2034: Medtronic Leads the Fragmented Market, Followed by Boston Scientific and Johnson & Johnson The global surgical meshes market is expected to grow from $2.02 billion in 2024 to $3.77 billion in 2034, with Medtronic, Boston Scientific, and Johnson & Johnson leading the fragmented market. The report highlights opportunities in various segments and regions, as well as key market trends and mergers and acquisitions."
2025-02-21 10:00:00+00:00,https://www.globenewswire.com/news-release/2025/02/21/3030284/0/en/Yaqrit-strengthens-board-and-senior-management-ahead-of-multi-prong-clinical-push-in-advanced-liver-disease.html,"Yaqrit strengthens board and senior management ahead of multi-prong clinical push in advanced liver disease Yaqrit, a late-stage clinical company developing treatments for advanced liver diseases, has appointed several key senior personnel to its board and management team to support its clinical development and commercialization strategy."
2025-02-21 18:00:00+00:00,https://www.globenewswire.com/news-release/2025/02/21/3030616/0/en/CAPLYTA-s-Strong-Market-Adoption-Propels-Its-Rise-as-a-Leading-Antipsychotic-Therapy-DelveInsight.html,"CAPLYTAâ€™s Strong Market Adoption Propels Its Rise as a Leading Antipsychotic Therapy | DelveInsight Intra-Cellular Therapies' CAPLYTA, an antipsychotic drug, is gaining traction in the market for treating schizophrenia and bipolar depression, with its differentiated safety profile and broad efficacy."
2025-02-24 12:30:00+00:00,https://www.fool.com/investing/2025/02/24/2-very-healthy-high-yield-dividend-stocks-to-buy-f/?source=iedfolrf0000001,"2 Very Healthy High-Yield Dividend Stocks to Buy for a Safe and Growing Passive Income Stream Medtronic and Johnson & Johnson are two high-yielding dividend stocks with strong financial profiles, enabling them to maintain and grow their dividends. Both companies have long histories of dividend increases, making them attractive options for investors seeking a reliable passive income stream."
2025-02-24 15:00:00+00:00,https://www.globenewswire.com/news-release/2025/02/24/3031261/0/en/Questex-s-Fierce-Pharma-Unveils-the-Conference-Program-for-the-Inaugural-Fierce-Pharma-Engage-Over-100-Speakers-Confirmed-to-Deliver-Unparalleled-Education.html,"Questexâ€™s Fierce Pharma Unveils the Conference Program for the Inaugural Fierce Pharma Engage, Over 100 Speakers Confirmed to Deliver Unparalleled Education Questex's Fierce Pharma has unveiled the conference program for the inaugural Fierce Pharma Engage, an exclusive summit for pharma and biotech marketing, dealmaking, communications and medical affairs executives. The event will feature over 100 speakers from leading pharmaceutical and biotechnology companies."
2025-02-24 18:00:00+00:00,https://www.globenewswire.com/news-release/2025/02/24/3031431/0/en/TALTZ-s-Rapid-Market-Ascent-Reflects-its-Unparalleled-Ability-to-Transform-the-Treatment-Landscape-for-Autoimmune-Diseases-DelveInsight.html,"TALTZâ€™s Rapid Market Ascent Reflects its Unparalleled Ability to Transform the Treatment Landscape for Autoimmune Diseases | DelveInsight TALTZ (ixekizumab), an IL-17A inhibitor by Eli Lilly, has shown strong market growth driven by increasing adoption in psoriasis, psoriatic arthritis, and axial spondyloarthritis. With expanding indications and competitive efficacy, it continues to gain market share against rivals."
2025-02-25 12:41:00+00:00,https://www.investing.com/analysis/3-dividendpaying-stocks-bucking-the-markets-trend-200657715,"3 Dividend-Paying Stocks Bucking the Marketâ€™s Trend Despite the broader market downturn, Coca-Cola, Johnson & Johnson, and McDonald's have shown resilience, with their dividend-paying stocks outperforming the market."
2025-02-25 18:00:00+00:00,https://www.globenewswire.com/news-release/2025/02/25/3032330/0/en/Comprehensive-Market-Analysis-of-Latest-Published-Different-Types-of-Depression-Reports-DelveInsight.html,"Comprehensive Market Analysis of Latest Published Different Types of Depression Reports | DelveInsight The depression treatment market is experiencing steady growth, driven by rising mental health awareness, increasing prevalence of depression, and advancements in novel therapies. The market is expanding with the introduction of innovative antidepressants, psychedelic-based treatments, and digital therapeutics."
2025-02-27 13:00:00+00:00,https://www.globenewswire.com/news-release/2025/02/27/3033776/0/en/Latin-American-Remote-Tech-Talent-Expands-BairesDev-Sees-285-Surge-in-Remote-Applicants-in-2024.html,"Latin American Remote Tech Talent Expands: BairesDev Sees 285% Surge in Remote Applicants in 2024 The article highlights four key trends shaping the tech industry in 2025: the rise of Latin America as a global tech player, the emergence of 'Silicon Pueblos', the growing demand for AI talent, and the importance of infrastructure and tech education in the region."
2025-02-28 10:06:00+00:00,https://www.fool.com/investing/2025/02/28/wall-street-greatest-dividend-stock-made-history/?source=iedfolrf0000001,"Wall Street's Greatest Dividend Stock Just Made History Again -- and 99.9% of Investors Have Never Heard of This Small-Cap Company York Water, a small-cap water utility company, has paid a continuous dividend for 209 consecutive years, the longest streak of any U.S. company. The company's predictable cash flow, regulated pricing, and strategic acquisitions have enabled its long-standing dividend payments."
2025-02-28 13:01:00+00:00,https://www.globenewswire.com/news-release/2025/02/28/3034707/0/en/Johnson-Johnson-s-DARZALEX-daratumumab-subcutaneous-based-regimen-receives-positive-CHMP-opinion-for-patients-with-newly-diagnosed-multiple-myeloma-regardless-of-transplant-eligibi.html,"Johnson & Johnsonâ€™s DARZALEXÂ® (daratumumab) subcutaneous-based regimen receives positive CHMP opinion for patients with newly diagnosed multiple myeloma, regardless of transplant eligibility Johnson & Johnson's DARZALEXÂ® (daratumumab) subcutaneous-based regimen has received a positive opinion from the CHMP for the treatment of adult patients with newly diagnosed multiple myeloma, regardless of transplant eligibility."
2025-03-01 10:51:00+00:00,https://www.fool.com/investing/2025/03/01/3-dividend-stocks-that-are-no-brainer-buys-right/?source=iedfolrf0000001,"3 Dividend Stocks That Are No-Brainer Buys Right Now Three Motley Fool contributors recommend Johnson & Johnson, Novartis, and Pfizer as no-brainer dividend stocks due to their strong balance sheets, diversified businesses, and ability to navigate regulatory changes."
2025-03-01 13:45:00+00:00,https://www.globenewswire.com/news-release/2025/03/01/3035103/0/en/International-Myeloma-Foundation-IMF-Celebrates-Myeloma-Milestones-for-2025-Myeloma-Action-Month.html,"International Myeloma Foundation (IMF) Celebrates Myeloma Milestones for 2025 Myeloma Action Month Myeloma Action Month is an annual global awareness campaign that takes place every March to raise awareness and inspire action for multiple myeloma, a blood cancer affecting over 176,404 people worldwide. This year, the International Myeloma Foundation invites individuals to share their most meaningful myeloma milestones, celebrating resilience, strengthening connections, and inspiring hope."
2025-03-02 12:38:00+00:00,https://www.fool.com/investing/2025/03/02/3-top-high-yield-dividend-stocks-i-plan-to-buy-in/?source=iedfolrf0000001,"3 Top High-Yield Dividend Stocks I Plan to Buy in March for More Passive Income The author plans to invest in PepsiCo, Johnson & Johnson, and Prologis to generate passive income through their high-yielding and steadily increasing dividends. The companies are well-positioned to continue growing their payouts due to their strong financial profiles and growth prospects."
2025-03-04 15:55:00+00:00,https://www.globenewswire.com/news-release/2025/03/04/3036739/28124/en/2025-Market-Prospects-of-Adeno-Associated-Virus-Vectors-in-Gene-Therapy-Pipeline-200-Pipeline-Drugs-and-the-Strategic-Workings-of-180-Companies.html,"2025 Market Prospects of Adeno-Associated Virus Vectors in Gene Therapy Pipeline: 200 Pipeline Drugs and the Strategic Workings of 180+ Companies The report provides a comprehensive analysis of the Adeno-Associated Virus (AAV) Vectors in Gene Therapy pipeline, highlighting the potential of this technology to revolutionize the treatment of genetic disorders. It examines the challenges in scalable production and safety, as well as the industry's focus on optimizing vectors for improved safety, specificity, and efficiency."
2025-03-04 18:00:00+00:00,https://www.globenewswire.com/news-release/2025/03/04/3036869/0/en/BALVERSA-Adoption-on-the-Rise-Meeting-Unmet-Needs-in-Advanced-Urothelial-Cancer-DelveInsight.html,"BALVERSA Adoption on the Rise: Meeting Unmet Needs in Advanced Urothelial Cancer | DelveInsight BALVERSA (erdafitinib), a targeted therapy for FGFR-altered urothelial carcinoma, has strong market potential as precision oncology gains emphasis. Its uptake is expected to increase, especially if expanded to earlier treatment lines or additional FGFR-driven tumors."
2025-03-04 18:00:00+00:00,https://www.globenewswire.com/news-release/2025/03/04/3036868/0/en/Global-Operating-Room-Equipment-Market-is-Predicted-to-Cross-USD-40-Billion-by-2032-DelveInsight.html,"Global Operating Room Equipment Market is Predicted to Cross ~USD 40 Billion by 2032 | DelveInsight The operating room equipment market is experiencing strong growth, driven by the increasing volume of surgical procedures and the growing incidence of chronic diseases, particularly among the aging population. North America is expected to dominate the market, with technological advancements and investments in research and development by key players fueling the demand for cutting-edge operating room equipment."
2025-03-10 10:11:00+00:00,https://www.fool.com/investing/2025/03/10/is-the-vanguard-high-dividend-yield-etf-the-smarte/?source=iedfolrf0000001,"Is the Vanguard High Dividend Yield ETF the Smartest Investment You Can Make Today? The Vanguard High Yield Dividend ETF (VYM) is a smart investment option during the current market uncertainty, as it provides consistent dividend income and is diversified across sectors. The ETF has a low expense ratio and its top holdings are well-established blue-chip stocks."
2025-03-12 12:48:00+00:00,https://www.globenewswire.com/news-release/2025/03/12/3041385/28124/en/Bispecific-Antibody-Market-Opportunity-Drug-Dosage-Patent-Price-Sales-Clinical-Trials-Insight-2030-New-Report-Highlights-600-Bispecific-Antibodies-in-Clinical-Trials-Worldwide.html,"Bispecific Antibody Market Opportunity, Drug Dosage, Patent, Price, Sales & Clinical Trials Insight 2030: New Report Highlights 600+ Bispecific Antibodies in Clinical Trials Worldwide The bispecific antibody market is experiencing rapid growth, projected to reach $50 billion by 2030. This is driven by increasing clinical trials, with over 600 candidates under development. Leading therapies like Hemlibra and Vabysmo (Roche) have already dominated 75% of sales, while emerging treatments like Linvoseltamab and Odronextamab are under FDA review."
2025-03-13 11:00:00+00:00,https://www.globenewswire.com/news-release/2025/03/13/3042017/0/en/AC-Immune-Reports-Full-Year-2024-Financial-Results-and-Provides-a-Corporate-Update.html,"AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update AC Immune reported positive clinical data for its pipeline of neurodegenerative disease therapies, including ACI-24.060, ACI-35.030, and ACI-7104.056. The company also signed a landmark $2.1 billion deal with Takeda for ACI-24.060 and received milestone payments from Janssen, ensuring funding into 2027."
2025-03-18 08:34:00+00:00,https://www.fool.com/investing/2025/03/18/got-300-buy-these-3-top-dividend-stocks-and-never/?source=iedfolrf0000001,"Got $300? Buy These 3 Top Dividend Stocks and Never Look Back. The article highlights three dividend stocks - Realty Income, Johnson & Johnson, and Brookfield Infrastructure - that have consistently increased their dividends over the years and are expected to continue this trend due to the durability of their businesses and long-term growth prospects."
2025-03-18 16:17:33+00:00,https://www.benzinga.com/general/biotech/25/03/44380787/fda-grants-fast-track-review-to-johnson-johnsons-nipocalimab-for-autoimmune-disorder-that-affects,"FDA Grants Fast Track Review To Johnson & Johnson's Nipocalimab For Autoimmune Disorder That Affects Tears, Saliva The FDA has granted Fast Track designation to Johnson & Johnson's investigational nipocalimab for the treatment of moderate-to-severe SjÃ¶gren's disease, a chronic autoimmune disorder affecting tear and saliva production. Phase 2 trial results showed significant improvements in disease activity and IgG levels with nipocalimab."
2025-03-20 08:45:00+00:00,https://www.fool.com/investing/2025/03/20/honeywell-not-let-breakup-ruin-growth-plan/?source=iedfolrf0000001,"Honeywell Isn't Going to Let a Little Breakup Ruin Its Growth Plans Honeywell is undergoing a complex restructuring, breaking up into three businesses while also acquiring Sundyne. This strategy increases uncertainty, as management juggles multiple corporate transactions. The breakup is happening from a position of strength, but the additional acquisition adds complexity to the process."
2025-03-21 16:31:09+00:00,https://www.benzinga.com/general/biotech/25/03/44440233/pharmaceutical-firms-say-uk-investment-is-unlikely-unless-payment-levy-is-adressed,"Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed UK pharmaceutical companies must pay 23.5%-35.6% of branded medicine sales revenue to the NHS, significantly higher than other European nations. This has led to a decline in the UK's share of global pharma R&D investment and medicine availability, prompting industry leaders to urge the government to address the excessive levies."
2025-03-26 18:40:22+00:00,https://www.benzinga.com/general/biotech/25/03/44500942/jj-drug-combo-outperforms-leading-lung-cancer-treatment-in-survival-study,"J&J Drug Combo Outperforms Leading Lung Cancer Treatment In Survival Study Johnson & Johnson's Rybrevant plus Lazcluze combination significantly extended overall survival beyond three years in first-line EGFR-mutated non-small cell lung cancer, surpassing AstraZeneca's Tagrisso (osimertinib)."
2025-03-27 09:25:00+00:00,https://www.fool.com/investing/2025/03/27/2-recession-proof-dividend-stocks-to-buy-and-hold/?source=iedfolrf0000001,"2 Recession-Proof Dividend Stocks to Buy and Hold Medtronic and Johnson & Johnson are healthcare companies that are well-positioned to weather a recession due to their diversified product portfolios, strong financial positions, and long histories of dividend growth. These factors make them attractive investment options for investors concerned about a potential economic downturn."
2025-03-27 14:59:00+00:00,https://www.globenewswire.com/news-release/2025/03/27/3050734/28124/en/Internet-of-Medical-Things-IoMT-Market-Forecast-2024-2029-2034-Revenues-to-Grow-from-US-97-73-Billion-in-2025-to-US-244-4-Billion-by-2029.html,"Internet of Medical Things (IoMT) Market Forecast 2024-2029 & 2034 - Revenues to Grow from US$97.73 Billion in 2025 to US$244.4 Billion by 2029 The Internet of Medical Things (IoMT) market is expected to grow exponentially, from $97.73 billion in 2025 to $244.4 billion by 2029, driven by factors like the rollout of 5G networks, telemedicine expansion, and the growing popularity of wearable devices."
2025-04-01 18:38:12+00:00,https://www.fool.com/investing/2025/04/01/why-johnson-johnson-stock-is-sinking-today/?source=iedfolrf0000001,"Why Johnson & Johnson Stock Is Sinking Today Johnson & Johnson's stock tumbled as a bankruptcy judge dismissed the company's $10 billion settlement attempt to resolve thousands of lawsuits alleging its baby powder caused ovarian cancer. The judge ruled the voting time was too short, and the company now plans to fight the cases individually."
2025-04-02 22:15:00+00:00,https://www.fool.com/investing/2025/04/02/worried-about-the-economy-2-no-brainer-buys/?source=iedfolrf0000001,"Worried About the Economy? 2 No-Brainer Buys to Shield Your Portfolio. The article discusses two stocks, Johnson & Johnson and Intuitive Surgical, that can help shield investors' portfolios from economic uncertainty. It highlights the companies' competitive advantages, growth potential, and resilience in various economic environments."
2025-04-03 16:30:42+00:00,https://www.benzinga.com/news/global/25/04/44631606/trumps-tariff-exemptions-include-semiconductors-pharmaceuticals-oil-and-more,"Trump's Tariff Exemptions Include Semiconductors, Pharmaceuticals, Oil And More President Trump announced new tariffs, but several industries were exempted, including semiconductors, pharmaceuticals, lumber, metals, and energy. The exemptions aim to avoid disruptions in critical supply chains."
2025-04-05 07:40:00+00:00,https://www.fool.com/investing/2025/04/05/trumps-tariffs-3-things-to-protect-portfolio/?source=iedfolrf0000001,"President Trump's Tariffs Have Arrived. 3 Things to Do to Protect Your Portfolio. The article discusses strategies for investors to protect their portfolios amid the market turmoil caused by the broader-than-expected tariff announcement by President Trump. It suggests holding on to well-established companies, considering companies that may benefit from the tariffs, and investing in Dividend Kings for passive income."
2025-04-06 08:46:00+00:00,https://www.fool.com/investing/2025/04/06/all-the-stocks-warren-buffett-bought-in-the-last-2/?source=iedfolrf0000001,"All the Stocks Warren Buffett Bought in the Last 2 Recessions: Are They Smart Picks Now? Warren Buffett, the legendary investor, has built a substantial cash stockpile for Berkshire Hathaway, preparing to be 'greedy when others are fearful' during a potential recession. The article examines the stocks Buffett bought during the Great Recession and the COVID-19 pandemic, and analyzes which of them could be smart picks now."
2025-04-08 04:50:00+00:00,https://www.globenewswire.com/news-release/2025/04/08/3057300/0/en/Global-Cosmeceuticals-Market-Size-to-Reach-USD-182-17-Bn-by-2032-at-a-CAGR-of-9-6-says-Coherent-Market-Insights.html,"Global Cosmeceuticals Market Size to Reach USD 182.17 Bn by 2032, at a CAGR of 9.6%, says Coherent Market Insights The global cosmeceuticals market is expected to grow rapidly, reaching $182.17 billion by 2032 at a CAGR of 9.6%. Key drivers include increasing consumer awareness, demand for natural and organic products, and the rise of nutricosmetics and personalized skincare."
2025-04-08 08:52:00+00:00,https://www.globenewswire.com/news-release/2025/04/08/3057376/28124/en/Ophthalmology-Market-Report-2025-Industry-to-Reach-US-93-7-Billion-by-2030-Emerging-Research-Activities-of-Ophthalmology-Treatments-and-Availability-of-Grants-Present-Business-Oppo.html,"Ophthalmology Market Report 2025 | Industry to Reach US$93.7 Billion by 2030 | Emerging Research Activities of Ophthalmology Treatments and Availability of Grants Present Business Opportunities The global ophthalmology market is expected to grow at a CAGR of 6.62%, reaching $93.69 billion by 2030, driven by advancements in technology, personalized medicine, and improved healthcare access."
2025-04-08 12:17:00+00:00,https://www.investing.com/analysis/2-defensive-sectors-to-protect-your-portfolio-during-a-recession-200659222,"2 Defensive Sectors to Protect Your Portfolio During a Recession As recession fears rise, investors are seeking defensive sectors to protect their portfolios. The article highlights Consumer Staples and Utilities as two sectors that tend to outperform during economic downturns."
2025-04-08 18:26:32+00:00,https://www.benzinga.com/general/biotech/25/04/44698541/johnson-johnsons-new-compelling-data-shows-sustained-symptom-improvement-in-muscular-disease-pati,"Johnson & Johnson's New 'Compelling Data' Shows Sustained Symptom Improvement In Muscular Disease Patients Johnson & Johnson's drug nipocalimab showed sustained improvements in symptoms and reduced steroid use in patients with generalized myasthenia gravis over 84 weeks, according to new data from the Phase 3 Vivacity-MG3 study and ongoing open-label extension."
2025-04-10 05:30:00+00:00,https://www.globenewswire.com/news-release/2025/04/10/3058973/0/en/Intramedullary-Nail-Market-size-to-worth-USD-1-537-Million-by-2032-says-Coherent-Market-Insights.html,"Intramedullary Nail Market size to worth USD 1,537 Million by 2032, says Coherent Market Insights The global intramedullary nail market is expected to grow rapidly, driven by the rising incidence of bone fractures, particularly among the aging population, and advancements in surgical techniques. However, the market faces challenges such as high procedural costs, the need for skilled professionals, and competition from alternative fixation devices."
2025-04-10 07:51:00+00:00,https://www.fool.com/investing/2025/04/10/dow-crash-4260-points-3-dow-stocks-no-brainer-buys/?source=iedfolrf0000001,"The Dow Crashed 4,260 Points in 3 Days: Here Are 3 Dow Stocks That Make for No-Brainer Buys Right Now The Dow Jones Industrial Average experienced a significant decline of 4,260 points over three trading sessions. The article identifies three Dow stocks - Visa, Johnson & Johnson, and Walt Disney - as potential buying opportunities for long-term investors due to their competitive advantages and growth prospects."
2025-04-10 09:59:00+00:00,https://www.globenewswire.com/news-release/2025/04/10/3059057/28124/en/Biopharmaceuticals-Global-Overview-Report-2025-Global-Market-to-Reach-698-7-Billion-by-2030-Fueled-by-Specialized-Therapies-Such-as-mAb-and-Gene-Treatments-a-Strong-Pipeline.html,"Biopharmaceuticals Global Overview Report 2025: Global Market to Reach $698.7 Billion by 2030, Fueled by Specialized Therapies, Such as mAb and Gene Treatments, & a Strong Pipeline The global biopharmaceuticals market is projected to grow to $698.7 billion by 2030, driven by the rising demand for specialized therapies like monoclonal antibodies and gene treatments, as well as advancements in technology and increased healthcare spending."
2025-04-11 08:25:00+00:00,https://www.fool.com/investing/2025/04/11/2-top-dividend-stocks-to-buy-right-now/?source=iedfolrf0000001,"2 Top Dividend Stocks to Buy Right Now Despite recent setbacks, Microsoft and Johnson & Johnson remain strong companies with impressive track records and growth prospects. Microsoft's cloud computing and AI leadership provide long-term tailwinds, while Johnson & Johnson's pharmaceutical and medtech businesses remain robust. Both companies have rock-solid dividend programs, making them attractive for long-term, dividend-seeking investors."
2025-04-11 13:36:46+00:00,https://www.benzinga.com/general/biotech/25/04/44761201/novartis-commits-23-billion-to-expand-us-manufacturing-over-five-years-despite-tariffs-uncertaint,"Novartis Commits $23 Billion To Expand US Manufacturing Over Five Years, Despite Tariffs Uncertainties Novartis announced a $23 billion investment plan to expand its manufacturing and research infrastructure in the U.S. over the next five years, including building new facilities and expanding existing ones."
2025-04-15 13:09:10+00:00,https://www.benzinga.com/general/biotech/25/04/44812561/johnson-johnson-q1-earnings-strong-cancer-drug-sales-boosts-quarterly-dividend-anticipates-negati,"Johnson & Johnson Q1 Earnings: Strong Cancer Drug Sales, Boosts Quarterly Dividend, Anticipates Negative Currency Impact For 2025 Profit Johnson & Johnson reported strong Q1 earnings, driven by cancer drug sales. The company raised its 2025 sales forecast and increased its quarterly dividend, but anticipates a negative currency impact on profits."
2025-04-16 14:50:00+00:00,https://www.globenewswire.com/news-release/2025/04/16/3062724/0/it/Miastenia-gravis-generalizzata-gMG-Johnson-Johnson-mette-in-luce-nuovi-dati-che-dimostrano-il-controllo-sostenuto-di-malattia-a-lungo-termine-nei-soggetti-adulti-affetti.html,"Miastenia gravis generalizzata (gMG): Johnson & Johnson mette in luce nuovi dati che dimostrano il controllo sostenuto di malattia a lungo termine nei soggetti adulti affetti Johnson & Johnson presented new data from the Phase 3 Vivacity-MG3 study and its open-label extension, demonstrating sustained improvements in symptoms and reduction in autoantibody levels in adults with generalized myasthenia gravis (gMG) over 18 months."
2025-04-17 08:51:00+00:00,https://www.fool.com/investing/2025/04/17/4-reasons-johnson-johnson-could-be-the-perfect-sto/?source=iedfolrf0000001,"4 Reasons Johnson & Johnson Could Be the Perfect Stock to Own in Today's Turbulent Market Johnson & Johnson is a healthcare giant that has shown remarkable resilience in turbulent markets. The company's diversified business, strong pipeline, and consistent dividend growth make it an attractive investment option in the current market environment."
2025-04-19 14:30:00+00:00,https://www.fool.com/investing/2025/04/19/3-top-dividend-stocks-yielding-over-3-to-buy-with/?source=iedfolrf0000001,"3 Top Dividend Stocks Yielding Over 3% to Buy With $500 Right Now The article highlights three dividend stocks - Johnson & Johnson, Invitation Homes, and NextEra Energy - that offer attractive dividend yields over 3% and have long histories of increasing their dividends. These stocks have the potential to turn a $500 investment into a growing stream of dividend income while also delivering solid stock price appreciation."
2025-04-20 11:30:00+00:00,https://www.fool.com/investing/2025/04/20/2-recession-proof-stocks-to-buy-with-a-better-cred/?source=iedfolrf0000001,"2 Recession-Proof Stocks to Buy With a Better Credit Rating Than the U.S. Government The article discusses two stocks, Microsoft and Johnson & Johnson, that have higher credit ratings than the U.S. government and can potentially weather a recession. Both companies have strong balance sheets and diversified businesses."
2025-04-22 19:21:26+00:00,https://www.benzinga.com/general/biotech/25/04/44934942/roche-plans-50-billion-us-investment-over-5-years-with-12000-new-jobs,"Roche Plans $50 Billion US Investment Over 5 Years With 12,000 New Jobs Roche Holding announced a $50 billion investment in the U.S. over the next 5 years, creating over 12,000 new jobs. The investment will expand Roche's manufacturing and R&D capabilities across several states."
2025-04-24 07:51:00+00:00,https://www.fool.com/investing/2025/04/24/trump-tariff-crash-2-dividend-stocks-buy-discount/?source=iedfolrf0000001,"In the Wake of the Trump Tariff Crash: 2 Unparalleled Dividend Stocks to Buy at a Discount Right Now The article discusses two dividend stocks, Johnson & Johnson and Sirius XM Holdings, that have become attractively priced following the recent market volatility caused by President Trump's tariff policies."
2025-04-24 09:25:00+00:00,https://www.fool.com/investing/2025/04/24/is-target-stock-high-yield-worth-it-in-2025/?source=iedfolrf0000001,"Is Target Stock's High Yield Worth It in 2025? Target aims to increase sales by $15 billion by 2030 through improvements to stores, supply chain, and technology. However, the company faces challenges from softening consumer demand in certain categories and the impact of tariffs on imported goods."
2025-04-24 12:34:00+00:00,https://www.fool.com/investing/2025/04/24/3-dividend-kings-that-have-raised-their-payouts-in/?source=iedfolrf0000001,"3 Dividend Kings That Have Raised Their Payouts in 2025 The article discusses three Dividend King stocks - Walmart, Johnson & Johnson, and Procter & Gamble - that have impressive track records of dividend growth and have recently raised their payouts. It analyzes the investment potential of these stocks based on their business performance, dividend growth streaks, and current valuations."
2025-04-25 07:00:00+00:00,https://www.globenewswire.com/news-release/2025/04/25/3068097/0/en/TREMFYA-guselkumab-receives-European-Commission-approval-for-adults-with-moderately-to-severely-active-ulcerative-colitis-strengthening-Johnson-Johnson-s-leadership-in-inflammatory.html,"TREMFYAÂ® (guselkumab) receives European Commission approval for adults with moderately to severely active ulcerative colitis, strengthening Johnson & Johnsonâ€™s leadership in inflammatory bowel disease The European Commission has approved TREMFYAÂ® (guselkumab), a fully-human, dual-acting interleukin-23 (IL-23) inhibitor, for the treatment of adult patients with moderately to severely active ulcerative colitis. This approval strengthens Johnson & Johnson's leadership in the inflammatory bowel disease market."
2025-04-26 14:15:00+00:00,https://www.fool.com/investing/2025/04/26/these-2-top-dividend-stocks-making-moves-to-avoid-/?source=iedfolrf0000001,"These 2 Top Dividend Stocks Are Making Moves to Avoid the Impact of Tariffs: Are They Buys? Johnson & Johnson and Novartis are investing in U.S. manufacturing to mitigate the impact of tariffs. Despite facing challenges, both companies have strong financials and consistent dividend growth, making them attractive investments."
2025-04-26 17:50:00+00:00,https://www.globenewswire.com/news-release/2025/04/26/3068773/0/en/Johnson-Johnson-s-TAR-200-monotherapy-demonstrates-highest-complete-response-rate-reported-to-date-with-sustained-clinical-benefits-in-patients-with-certain-types-of-bladder-cancer.html,"Johnson & Johnsonâ€™s TAR-200 monotherapy demonstrates highest complete response rate reported to date with sustained clinical benefits in patients with certain types of bladder cancer Johnson & Johnson's TAR-200 monotherapy achieved a high complete response rate of over 82% in patients with certain types of high-risk non-muscle invasive bladder cancer, with more than half of responders remaining cancer-free at one year. These results highlight the potential of TAR-200 as a breakthrough treatment for this patient population."
2025-04-26 18:00:00+00:00,https://www.globenewswire.com/news-release/2025/04/26/3068774/0/en/Johnson-Johnson-s-TAR-200-monotherapy-achieves-high-disease-free-survival-of-more-than-80-percent-in-BCG-unresponsive-high-risk-papillary-NMIBC.html,"Johnson & Johnsonâ€™s TAR-200 monotherapy achieves high disease-free survival of more than 80 percent in BCG-unresponsive, high-risk papillary NMIBC Johnson & Johnson's TAR-200 monotherapy demonstrated high disease-free survival rates and bladder preservation in patients with certain types of bladder cancer, showing the potential for TAR-200 as an effective and well-tolerated treatment alternative to surgery."
2025-04-28 17:22:00+00:00,https://www.investing.com/analysis/3-industry-behemoths-are-rewarding-investors-with-dividend-bumps-200660059,"3 Industry Behemoths Are Rewarding Investors With Dividend Bumps Johnson & Johnson, Costco Wholesale, and Nasdaq have announced significant increases to their quarterly dividend payments, demonstrating their commitment to shareholder value despite broader market volatility."
2025-04-29 10:00:00+00:00,https://www.globenewswire.com/news-release/2025/04/29/3069966/0/fr/Le-TAR-200-en-monoth%C3%A9rapie-de-Johnson-Johnson-pr%C3%A9sente-le-taux-de-r%C3%A9ponse-compl%C3%A8te-le-plus-%C3%A9lev%C3%A9-rapport%C3%A9-%C3%A0-ce-jour-avec-des-b%C3%A9n%C3%A9fices-cliniques-durables-chez-les-patients-atteints.html,"Le TAR-200Â en monothÃ©rapie de JohnsonÂ &Â Johnson prÃ©sente le taux de rÃ©ponse complÃ¨te le plus Ã©levÃ© rapportÃ© Ã  ce jour avec des bÃ©nÃ©fices cliniques durables chez les patients atteints de certains types de cancer de la vessie Johnson & Johnson's TAR-200 monotherapy achieved an 82% complete response rate in patients with high-risk non-muscle-invasive bladder cancer, with over half of responders remaining cancer-free for at least 12 months. These results highlight the potential of TAR-200 to address unmet needs in this patient population."
2025-04-30 08:56:00+00:00,https://www.globenewswire.com/news-release/2025/04/30/3071071/28124/en/Analysis-of-Cancer-Immunotherapy-Technologies-and-Global-Markets-to-2029-Merck-Roche-Bristol-Myers-Squibb-Company-Johnson-Johnson-Services-and-AstraZeneca-Dominate.html,"Analysis of Cancer Immunotherapy Technologies and Global Markets to 2029 - Merck, Roche, Bristol-Myers Squibb Company, Johnson & Johnson Services, and AstraZeneca Dominate The global cancer immunotherapy market is expected to grow from $144.2 billion in 2024 to $247.2 billion by 2029, driven by rising cancer cases, robust approval of immunotherapy drugs, and increased government funding and R&D spending. Key players in the market include Merck, Roche, Bristol-Myers Squibb, Johnson & Johnson, and AstraZeneca."
2025-05-04 08:49:00+00:00,https://www.fool.com/investing/2025/05/04/is-the-trump-administration-about-to-cause-abbvie/?source=iedfolrf0000001,"Is the Trump Administration About to Cause AbbVie, Eli Lilly, and Johnson & Johnson Stocks to Crash? The Trump administration is considering implementing policies such as tariffs and international reference pricing that could negatively impact pharmaceutical companies like AbbVie, Eli Lilly, and Johnson & Johnson. However, the author believes a crash is unlikely, as the companies have already taken steps to mitigate the potential impact and the policies may face legal challenges."
2025-05-07 13:21:00+00:00,https://www.investing.com/analysis/dividend-hikes-offer-optimism-amid-tariff-turmoil-200660480,"Dividend Hikes Offer Optimism Amid Tariff Turmoil Despite macro headwinds, many large US multinational corporations have announced dividend hikes, signaling optimism amid tariff turmoil. Dividend aristocrats like Procter & Gamble and Johnson & Johnson have increased their payouts, outperforming the broader market."
2025-05-12 17:00:00+00:00,https://www.globenewswire.com/news-release/2025/05/12/3079405/0/en/Blood-Cancer-Treatment-Market-Sees-Accelerated-Growth-Across-the-7MM-Amid-Rising-Incidence-and-Breakthroughs-DelveInsight.html,"Blood Cancer Treatment Market Sees Accelerated Growth Across the 7MM Amid Rising Incidence and Breakthroughs | DelveInsight The blood cancer market is experiencing robust growth, driven by rising incidence rates and advancements in targeted therapies and immuno-oncology. Increasing adoption of CAR-T cell therapies, monoclonal antibodies, and personalized medicine is transforming treatment outcomes."
2025-05-13 20:09:32+00:00,https://www.benzinga.com/economics/macro-economic-events/25/05/45390422/trump-unveils-historic-and-transformative-600-billion-saudi-deal-predicts-markets,"Trump Unveils 'Historic And Transformative' $600 Billion Saudi Deal, Predicts Markets Will 'Go A Lot Higher' President Trump announced a $600 billion investment commitment from Saudi Arabia into the U.S., including deals with major companies in tech, defense, and infrastructure."
2025-05-15 17:00:00+00:00,https://www.globenewswire.com/news-release/2025/05/15/3082520/0/en/Global-Intraocular-Lens-Market-to-Witness-Upsurge-in-Growth-at-a-CAGR-of-5-by-2032-DelveInsight.html,"Global Intraocular Lens Market to Witness Upsurge in Growth at a CAGR of ~5% by 2032 | DelveInsight The global intraocular lens market is expected to grow significantly due to the rising prevalence of eye diseases, increased government efforts to prevent and treat blindness, advancements in intraocular lens technologies, and an aging population more prone to eye disorders."
2025-05-17 08:20:00+00:00,https://www.fool.com/investing/2025/05/17/jamie-dimon-says-recession-risk-remains/?source=iedfolrf0000001,"Billionaire CEO Jamie Dimon Says a Recession Isn't ""Off the Table at This Point,"" Despite Lowering Tariffs. 5 Ways to Help Protect Your Stock Portfolio in Any Market Environment. Despite the recent U.S.-China trade deal, JPMorgan Chase CEO Jamie Dimon remains cautious about the economy, warning that a recession is still possible. The article provides five strategies to help protect your stock portfolio in any market environment."
2025-05-18 10:15:00+00:00,https://www.fool.com/investing/2025/05/18/meet-the-warren-buffett-stock-thats-gained-5502284/?source=iedfolrf0000001,"Meet the Warren Buffett Investment That's Gained 5,502,284% and Looks Set to Soar Even Higher Berkshire Hathaway, the investment vehicle of Warren Buffett, has generated a staggering 5,502,284% in total returns over the past 60 years, far outpacing the S&P 500. The article suggests that Berkshire Hathaway is well-positioned to continue thriving under the leadership of Greg Abel, who is set to take over from Buffett."
2025-05-23 09:48:00+00:00,https://www.globenewswire.com/news-release/2025/05/23/3087360/28124/en/Endoscopy-Devices-Global-Market-Overview-2021-2030-with-Forecasts-2024-2030-Rise-of-Ambulatory-Surgical-Centers-and-Disposable-Endoscopes-Boost-Market-Expansion.html,"Endoscopy Devices Global Market Overview 2021-2030 with Forecasts 2024-2030 - Rise of Ambulatory Surgical Centers and Disposable Endoscopes Boost Market Expansion The global endoscopy devices market is projected to grow from $59 billion in 2024 to $89 billion by 2030, driven by aging populations, chronic diseases, and technological advancements. North America dominates the market, while Asia Pacific is the fastest-growing region."
2025-05-24 08:16:00+00:00,https://www.fool.com/investing/2025/05/24/generating-passive-income-3-top-dow-dividend-stock/?source=iedfolrf0000001,"Generating Passive Income: 3 Top Dow Dividend Stocks to Buy for 2025 and Beyond The article highlights three Dow Jones Industrial Average stocks - Chevron, Johnson & Johnson, and Verizon - as top income-generating investments for the long term due to their high dividend yields and growth potential."
2025-05-25 08:10:00+00:00,https://www.fool.com/investing/2025/05/25/heres-what-history-says-dividend-kings/?source=iedfolrf0000001,"Investing for Passive Income? Here's What History Says About the Stability of Dividend King Stocks. Investing in Dividend King stocks, which have raised dividends for at least 50 consecutive years, can provide stable passive income and cushion portfolio performance during tough market times. History shows these stocks have delivered strong long-term returns, with dividends contributing significantly to overall gains."
2025-05-26 14:56:00+00:00,https://www.globenewswire.com/news-release/2025/05/26/3088176/28124/en/U-S-Ophthalmic-Photocoagulator-Growth-Trends-and-Forecasts-2025-2032-Market-Expands-Amid-Surge-in-Diabetic-Retinopathy-Cases.html,"U.S. Ophthalmic Photocoagulator Growth Trends and Forecasts 2025-2032 - Market Expands Amid Surge in Diabetic Retinopathy Cases The U.S. ophthalmic photocoagulator market is expected to grow from $52.62 million in 2025 to $74.3 million by 2032, driven by the increasing prevalence of eye conditions like diabetic retinopathy. Adoption of advanced multicolor laser technologies and the shift towards outpatient treatments are key trends, while reimbursement issues and competition from alternative therapies pose challenges."
2025-05-27 14:56:00+00:00,https://www.globenewswire.com/news-release/2025/05/27/3088804/28124/en/Schizophrenia-Drugs-Market-Research-Report-2025-2035-Advances-in-Antipsychotic-Drug-Development-Increasing-Prevalence-Greater-Awareness-and-Access-to-Mental-Health-Care-Bolster-Gro.html,"Schizophrenia Drugs Market Research Report 2025-2035: Advances in Antipsychotic Drug Development, Increasing Prevalence, & Greater Awareness and Access to Mental Health Care Bolster Growth The schizophrenia drugs market is experiencing significant changes, with the emergence of new treatments like ketamine-based therapies. North America is expected to continue leading the global market due to well-established healthcare infrastructure and increasing government funding for mental health initiatives."
2025-05-27 16:00:35+00:00,https://www.benzinga.com/news/large-cap/25/05/45623176/why-dan-loeb-just-made-kenvue-one-of-his-top-holdings,"Why Dan Loeb Just Made Kenvue One Of His Top Holdings Activist investor Dan Loeb's Third Point LLC acquired a significant stake in consumer health company Kenvue, making it one of his top five holdings. Kenvue updated its fiscal 2025 outlook, and its Q1 sales beat consensus."
2025-05-27 19:44:51+00:00,https://www.benzinga.com/general/biotech/25/05/45629452/why-is-teva-stock-trading-higher-on-tuesday,"Why Is Teva Stock Trading Higher On Tuesday? Teva Pharmaceutical and Biolojic Design announced that Teva initiated IND-enabling studies with BD9, a dual-specific multibody targeting both TSLP and IL-13, which can potentially improve outcomes for patients with conditions such as atopic dermatitis and asthma."
2025-05-30 08:56:00+00:00,https://www.globenewswire.com/news-release/2025/05/30/3090910/28124/en/The-World-Market-for-Smoking-Cessation-Nicotine-De-Addiction-Products-2025-2030-Precision-Counseling-Targeted-Pharmacogenomic-Therapies-and-Resilient-Supply-Chains-Present-Lucrativ.html,"The World Market for Smoking Cessation & Nicotine De-Addiction Products 2025-2030: Precision Counseling, Targeted Pharmacogenomic Therapies, and Resilient Supply Chains Present Lucrative Opportunities The global smoking cessation and nicotine de-addiction product market is expected to grow significantly from 2025 to 2030, driven by advancements in digital health, personalized medicine, and regulatory frameworks. Key players in the market include Johnson & Johnson, GlaxoSmithKline, Pfizer, Novartis, and Teva Pharmaceutical Industries."
2025-06-02 16:07:00+00:00,https://www.investing.com/analysis/healthcare-setting-up-for-a-catchup-trade-in-h2-charts-suggest-maybe-200661565,"Healthcare Sector Setting Up for a Catch-Up Trade in H2? The healthcare sector has faced several headwinds in 2025, leading to lower earnings growth expectations. However, the sector is still expected to be one of the strongest performers in the S&P 500 this year, and some individual stocks and ETFs have shown resilience."
2025-06-03 18:14:34+00:00,https://www.benzinga.com/news/health-care/25/06/45755748/johnson-johnson-highlights-multiple-blood-cancer-trial-data-at-asco-presentation,"Johnson & Johnson Highlights Multiple Blood Cancer Trial Data At ASCO Presentation Johnson & Johnson released promising data from several cancer studies, including positive results for niraparib plus abiraterone acetate in prostate cancer, and long-term follow-up data showing 33% of multiple myeloma patients treated with CARVYKTI achieved 5-year remission."
2025-06-10 08:53:00+00:00,https://www.globenewswire.com/news-release/2025/06/10/3096389/28124/en/Rheumatoid-Arthritis-Global-Market-Research-Report-2025-2035-TNF-Inhibitors-IL-6-Inhibitors-and-JAK-Inhibitors-at-the-Forefront-of-Developing-Biologic-Therapies.html,"Rheumatoid Arthritis Global Market Research Report 2025-2035: TNF Inhibitors, IL-6 Inhibitors, and JAK Inhibitors at the Forefront of Developing Biologic Therapies The global rheumatoid arthritis market is highly competitive, with major pharmaceutical companies leading the development of innovative biologic therapies such as TNF inhibitors, IL-6 inhibitors, and JAK inhibitors. However, challenges like high costs and accessibility hinder the market's growth."
2025-06-12 08:12:00+00:00,https://www.fool.com/investing/2025/06/12/if-i-could-invest-1000-in-any-growth-stock-it-woul/?source=iedfolrf0000001,"If I Could Invest $1,000 in Any Growth Stock, It Would Be This One Alphabet, the parent company of Google, is a growth stock trading at a discount compared to the broader market and its peers. Despite concerns about the concentration of its advertising revenue, the company's cloud computing business is growing rapidly and profitably, positioning it well for the future."
2025-06-15 07:15:00+00:00,https://www.globenewswire.com/news-release/2025/06/15/3099407/0/en/Investigational-combination-of-first-in-class-bispecific-antibodies-TALVEY-talquetamab-and-TECVAYLI-teclistamab-shows-deep-and-durable-responses-in-heavily-pretreated-multiple-myel.html,"Investigational combination of first-in-class bispecific antibodies TALVEYÂ®â–¼ (talquetamab) and TECVAYLIÂ®â–¼ (teclistamab) shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease The investigational combination of talquetamab and teclistamab, two bispecific antibodies, demonstrated deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease, a particularly aggressive form of the disease."
2025-06-18 09:02:00+00:00,https://www.fool.com/investing/2025/06/18/2-dividend-stocks-to-buy-and-never-sell/?source=iedfolrf0000001,"2 Dividend Stocks to Buy and Never Sell Johnson & Johnson and Merck are two excellent dividend stocks for long-term, income-oriented investors. Despite facing some challenges, both companies have strong underlying businesses, deep pipelines, and a history of consistent dividend increases."
2025-06-25 07:00:00+00:00,https://www.globenewswire.com/news-release/2025/06/25/3104815/0/en/Nipocalimab-showed-greater-sustained-disease-control-versus-approved-FcRn-blockers-for-generalised-myasthenia-gravis-gMG-at-multiple-timepoints-over-24-weeks-in-newly-published-ind.html,"Nipocalimab showed greater sustained disease control versus approved FcRn blockers for generalised myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly published indirect treatment comparison (ITC) Nipocalimab, an FcRn blocker, showed consistent and sustained disease control with greater or statistically significant improvement in MG-ADL scores versus other approved FcRn blockers for treating generalized myasthenia gravis (gMG) in an indirect treatment comparison."
2025-06-25 07:00:00+00:00,https://www.globenewswire.com/news-release/2025/06/25/3104815/0/it/In-uno-studio-di-confronto-indiretto-ITC-pubblicato-di-recente-nipocalimab-ha-mostrato-un-controllo-pi%C3%B9-sostenuto-della-malattia-rispetto-ai-bloccanti-di-FcRn-approvati-per-la-mias.html,"In uno studio di confronto indiretto (ITC) pubblicato di recente, nipocalimab ha mostrato un controllo piÃ¹ sostenuto della malattia rispetto ai bloccanti di FcRn approvati per la miastenia grave generalizzata (gMG) in diversi momenti nellâ€™a A recent indirect treatment comparison (ITC) study showed that nipocalimab, an FcRn blocker, provided more sustained disease control compared to other approved FcRn blockers for generalized myasthenia gravis (gMG) at various time points."
2025-06-27 08:12:00+00:00,https://www.fool.com/investing/2025/06/27/johnson-johnson-great-why-shouldnt-buy-stock/?source=iedfolrf0000001,"Johnson & Johnson Is Great. Here's Why You Shouldn't Buy It. Despite Johnson & Johnson's strong financial performance, dividend history, and market leadership, the ongoing talcum powder lawsuit liabilities create significant uncertainty that makes the stock unattractive for investment."
2025-07-01 10:26:00+00:00,https://www.fool.com/investing/2025/07/01/1-no-brainer-sp-index-fund-buy-right-now-for-less-/?source=iedfolrf0000001,"1 No-Brainer S&P Index Fund to Buy Right Now for Less Than $1,000 The iShares Core S&P 500 ETF (IVV) offers investors a low-cost, diversified way to invest in the U.S. stock market by tracking the S&P 500 index, providing steady long-term growth with minimal risk."
2025-07-04 06:00:00+00:00,https://www.globenewswire.com/news-release/2025/07/04/3110196/0/en/Str%C3%BCngmann-Award-Honors-Araris-Biotech-Founding-Team-as-2025-Winner.html,"StrÃ¼ngmann Award Honors Araris Biotech Founding TeamÂ as 2025 Winner Araris Biotech founders Dragan Grabulovski, Philipp Spycher, and Isabella Attinger-Toller won the 2025 StrÃ¼ngmann Award for their innovative antibody-drug conjugate technology in cancer therapy, receiving a â‚¬100,000 prize and recognition for their successful startup journey."
2025-07-04 06:00:00+00:00,https://www.globenewswire.com/news-release/2025/07/04/3110196/0/de/Str%C3%BCngmann-Award-zeichnet-Gr%C3%BCnderteam-von-Araris-Biotech-als-Preistr%C3%A4ger-2025-aus.html,"StrÃ¼ngmann Award zeichnet GrÃ¼nderteam von Araris Biotech als PreistrÃ¤ger 2025 aus Araris Biotech founders Dr. Dragan Grabulovski, Dr. Philipp Spycher, and Dr. Isabella Attinger-Toller won the 2025 StrÃ¼ngmann Award for developing innovative antibody-drug conjugate technology in cancer therapy, receiving a â‚¬100,000 prize after being acquired by Taiho Pharmaceutical."
2025-07-07 10:07:00+00:00,https://www.fool.com/investing/2025/07/07/should-you-forget-johnson-johnson-and-buy-this-mag/?source=iedfolrf0000001,"Should You Forget Johnson & Johnson and Buy This Magnificent High-Yield Dividend Stock Instead? The article compares Johnson & Johnson's dividend performance with Universal Health Realty Income Trust, highlighting the latter's significantly higher dividend yield of 7.4% versus J&J's 3.4%, and suggesting it might be more attractive for income-focused investors."
2025-07-07 18:21:38+00:00,https://www.benzinga.com/news/fda/25/07/46282484/fda-issues-early-alert-for-johnson-johnsons-abiomed-heart-pump-controllers,"FDA Issues Early Alert For Johnson & Johnson's Abiomed Heart Pump Controllers Johnson & Johnson's Abiomed unit received an FDA early alert regarding Automated Impella Controllers (AIC) for heart pumps, with potential detection issues that could compromise patient safety, resulting in three reported deaths."
2025-07-11 07:10:00+00:00,https://www.fool.com/investing/2025/07/11/2-dividend-stocks-to-double-up-on-right-now/?source=iedfolrf0000001,"2 Dividend Stocks to Double Up on Right Now The article highlights Johnson & Johnson and Coca-Cola as strong dividend stocks, both with over 60 consecutive years of dividend increases, offering stable passive income and potential growth opportunities in their respective industries."
2025-07-11 08:25:00+00:00,https://www.fool.com/investing/2025/07/11/the-best-high-yield-medical-device-stock-to-invest/?source=iedfolrf0000001,"The Best High Yield Medical Device Stock to Invest $1,000 in Right Now Medtronic, a global medical device company, offers an attractive investment opportunity with a 3.2% dividend yield, despite recent stock price challenges. The company is focusing on innovation, profitability improvements, and strategic business restructuring."
2025-07-12 10:05:00+00:00,https://www.fool.com/investing/2025/07/12/motley-fool-ceo-tom-gardner-sp-500-voo-at-25-earni/?source=iedfolrf0000001,"Motley Fool CEO Tom Gardner: S&P 500 (VOO) at 25Ã— Earnings Is Stretching Valuations Motley Fool CEO Tom Gardner suggests the S&P 500 is expensive at 26x earnings, but investors can find opportunities in value stocks, foreign stocks, and dividend stocks through strategic ETF investments."
2025-07-15 07:07:00+00:00,https://www.fool.com/investing/2025/07/15/buy-high-yield-dividend-stock-passive-income/?source=iedfolrf0000001,"Want to Generate at Least $1,000 in Passive Income Per Year? Invest $26,000 in This Dividend King Stock. Kenvue, a consumer health and hygiene company spun off from Johnson & Johnson, offers a high dividend yield of 3.9% despite recent challenges. Investors could potentially generate $1,000 in passive income by investing $26,000 in this stock."
2025-07-16 11:12:00+00:00,https://www.fool.com/investing/2025/07/16/3-magnificent-sp-500-dividend-stocks-down-16-to-20/?source=iedfolrf0000001,"3 Magnificent S&P 500 Dividend Stocks Down 16% to 20% to Buy and Hold Forever The article highlights three S&P 500 dividend stocks trading below their all-time highs: Johnson & Johnson, NextEra Energy, and Chevron. Each company offers strong dividend histories, consistent growth, and potential for long-term investment."
2025-07-16 17:44:56+00:00,https://www.benzinga.com/markets/equities/25/07/46450946/wall-street-wednesday-stock-movers-sp500-trump-powell-bitcoin-gold,"Gold, Bitcoin Surge As Trump Eyes Powell Ouster: What's Moving Markets Wednesday? Markets experienced volatility as rumors circulated about President Trump potentially removing Federal Reserve Chair Jerome Powell, causing gold and Bitcoin to surge while the dollar weakened. Economic data showed softer producer prices, reinforcing expectations of potential interest rate cuts."
2025-07-16 18:38:00+00:00,https://www.fool.com/investing/2025/07/16/why-johnson-johnson-rallied-today/?source=iedfolrf0000001,"Why Johnson & Johnson Rallied Today Johnson & Johnson reported strong Q2 earnings, beating expectations with $23.7 billion in revenue. The company's neuroscience segment grew 14.4% after acquiring Intra-Cellular Therapies, and management raised full-year guidance despite minor challenges from tariffs."
2025-07-16 22:01:00+00:00,https://www.fool.com/investing/2025/07/16/3-top-dividend-stocks-yielding-over-3-you-shouldnt/?source=iedfolrf0000001,"3 Top Dividend Stocks Yielding More Than 3% That You Shouldn't Hesitate to Buy Right Now With the S&P 500's dividend yield near record lows, three companies offer attractive dividend opportunities: ExxonMobil, Johnson & Johnson, and Essex Property Trust, each yielding over 3% with strong historical dividend growth and financial stability."
2025-07-17 04:39:12+00:00,https://www.benzinga.com/markets/equities/25/07/46459215/22nd-century-group-stock-jumps-75-after-hour-on-news-of-reduced-nicotine-push,"22nd Century Group Stock Jumps 75% After Hour On News Of Reduced-Nicotine Push 22nd Century Group's stock surged 75.76% in after-hours trading following an announcement of expanded partnerships for its reduced nicotine content tobacco products, despite challenging first-quarter earnings."
2025-07-17 10:05:00+00:00,https://www.fool.com/investing/2025/07/17/johnson-johnsons-healthy-33-yielding-dividend-is-a/?source=iedfolrf0000001,"Johnson & Johnson's Healthy 3.3%-Yielding Dividend Is a Very Safe Way to Make Passive Income Johnson & Johnson demonstrates a robust financial profile with a 63-year history of dividend increases, strong cash flow, and strategic investments in R&D and MedTech. The company expects continued growth, with plans to launch innovative medicine assets and maintain its elite dividend status."
2025-07-17 14:32:00+00:00,https://www.investing.com/analysis/johnson--johnson-is-back-in-rally-modethe-time-to-buy-is-now-200663874,"Johnson & Johnson Is Back in Rally Modeâ€”The Time to Buy Is Now Johnson & Johnson reported strong Q2 results with 5.8% earnings growth, showing strength in MedTech and Innovative Medicine segments. The company's stock is positioned for a potential rally, supported by positive financial performance and favorable market indicators."
2025-07-17 22:06:00+00:00,https://www.investing.com/analysis/are-these-dividend-stocks-the-safe-havens-investors-need-this-quarter-200663896,"Are These Dividend Stocks the Safe Havens Investors Need This Quarter? The article explores three dividend stocks that offer reliable income and potential growth during market volatility: Johnson & Johnson, Verizon Communications, and Duke Energy Corporation."
2025-07-18 08:58:00+00:00,https://www.globenewswire.com/news-release/2025/07/18/3117769/28124/en/Ophthalmics-Collaboration-and-Licensing-Deals-Report-and-Directory-2025-Company-A-Z-Therapy-Focus-Upfront-Milestone-Royalties.html,"Ophthalmics Collaboration and Licensing Deals Report and Directory 2025 | Company A-Z, Therapy Focus, Upfront, Milestone, Royalties A comprehensive report detailing 344 ophthalmics deals from 2019 to 2025, providing insights into collaboration and licensing agreements in the biopharma industry, with analysis of financial terms, deal trends, and key market participants."
2025-07-20 08:05:00+00:00,https://www.fool.com/investing/2025/07/20/the-smartest-dividend-stock-to-buy-with-1000-right/?source=iedfolrf0000001,"The Smartest Dividend Stock to Buy With $1,000 Right Now Universal Health Realty Income Trust offers a high 7.4% dividend yield, with a 40-year history of annual dividend increases. While attractive for income investors, it has slower dividend growth and potential conflicts of interest due to external management."
2025-07-20 09:01:00+00:00,https://www.fool.com/investing/general/2025/07/20/10-magnificent-sp-500-dividend-stocks-down-10-buy/?source=iedfolrf0000001,"10 Magnificent S&P 500 Dividend Stocks Down Over 10% to Buy and Hold Forever The article highlights 10 S&P 500 dividend stocks with strong financial performance, consistent dividend growth, and potential for long-term investment across various sectors including healthcare, energy, utilities, and technology."
2025-07-22 07:20:00+00:00,https://www.globenewswire.com/news-release/2025/07/22/3119172/0/en/Bispecific-Antibodies-Market-Set-to-Surge-to-163-15-Billion-by-2032-Driven-by-a-Robust-40-1-CAGR-Roche-Amgen-and-Johnson-Johnson-at-the-Forefront-AnalystView-Market-Insights.html,"Bispecific Antibodies Market Set to Surge to $163.15 Billion by 2032, Driven by a Robust 40.1% CAGR | Roche, Amgen, and Johnson & Johnson at the Forefront: AnalystView Market Insights The global bispecific antibodies market is expected to surge to $163.15 billion by 2032, driven by a 40.1% CAGR, with significant growth in oncology and immunology therapies targeting complex diseases."
2025-07-23 05:30:00+00:00,https://www.globenewswire.com/news-release/2025/07/23/3119981/0/fr/Ipsen-annonce-des-changements-au-sein-de-son-Comit%C3%A9-Ex%C3%A9cutif.html,"Ipsen annonce des changements au sein de son ComitÃ© ExÃ©cutif Ipsen has announced three key executive appointments: Mari Scheiffele as VP of Products, Andreas Gerber as International Director, and Caroline Sitbon as Legal Director, effective September 1st, 2025. These changes aim to strengthen leadership and achieve gender parity in the executive committee."
2025-07-23 05:30:00+00:00,https://www.globenewswire.com/news-release/2025/07/23/3119981/0/en/Ipsen-announces-changes-to-its-Executive-Committee.html,"Ipsen announces changes to its Executive Committee Ipsen has appointed Mari Scheiffele as Chief Product Officer, Andreas Gerber as Head of International, and Caroline Sitbon as General Counsel, effective September 1, 2025. These appointments bring new leadership to the company's executive team and represent a gender-balanced committee."
2025-07-23 12:37:00+00:00,https://www.investing.com/analysis/4-major-stocks-raise-2025-guidance-analyst-targets-rise-200664186,"4 Major Stocks Raise 2025 Guidance, Analyst Targets Rise Four major U.S. companies - Netflix, Levi Strauss, JPMorgan Chase, and Johnson & Johnson - raised their 2025 full-year guidance following strong Q2 earnings, prompting analysts to increase price targets across multiple sectors."
2025-07-23 17:00:00+00:00,https://www.globenewswire.com/news-release/2025/07/23/3120536/0/en/Global-Dysmenorrhea-Treatment-Market-to-Cross-USD-8-Billion-by-2032-DelveInsight.html,"Global Dysmenorrhea Treatment Market to Cross ~USD 8 Billion by 2032 | DelveInsight The dysmenorrhea treatment market is experiencing substantial growth driven by increased awareness, advanced diagnostics, and a growing demand for diverse treatment options including painkillers and hormonal therapies."
2025-07-24 17:08:43+00:00,https://www.benzinga.com/news/health-care/25/07/46610935/astrazeneca-prepares-showdown-with-jnj-amgen-with-phase-3-win-for-myasthenia-gravis-drug-candida,"AstraZeneca Prepares Showdown With JNJ, Amgen With Phase 3 Win For Myasthenia Gravis Drug Candidate AstraZeneca reported positive Phase 3 trial results for gefurulimab, a drug candidate treating generalized myasthenia gravis, demonstrating significant improvement in patient symptoms with no new safety concerns."
2025-07-25 14:50:00+00:00,https://www.globenewswire.com/news-release/2025/07/25/3121870/28124/en/Oncology-Drugs-Market-Insights-Competitive-Landscape-and-Forecast-Report-2025-2032-Immunotherapy-Leads-Growth-in-Oncology-Market-Due-to-Better-Precision-and-Fewer-Side-Effects.html,"Oncology Drugs Market Insights, Competitive Landscape, and Forecast Report 2025-2032 | Immunotherapy Leads Growth in Oncology Market Due to Better Precision and Fewer Side Effects Global oncology drugs market expected to grow at 6.87% CAGR, reaching $364.81 billion by 2032, driven by rising cancer cases and immunotherapy advancements, with North America leading market expansion."
2025-07-27 07:15:00+00:00,https://www.fool.com/investing/2025/07/27/these-3-dow-stocks-are-set-to-soar-in-2025-and-bey/?source=iedfolrf0000001,"These 3 Dow Stocks Are Set to Soar in 2025 and Beyond The article discusses three Dow Jones stocks with potential for growth: Apple, Walmart, and Johnson & Johnson, highlighting their current challenges and future opportunities in technology, retail, and oncology sectors."
2025-07-29 00:29:00+00:00,https://www.fool.com/investing/2025/07/28/x-unstoppable-dow-dividend-stocks-to-buy-and-hold/?source=iedfolrf0000001,"2 Unstoppable Dow Dividend Stocks to Buy and Hold Forever Johnson & Johnson and Verizon are highlighted as strong Dow dividend stocks with consistent cash flow, low debt, and long histories of dividend growth, making them attractive long-term investment options."
2025-07-29 17:51:00+00:00,https://www.globenewswire.com/news-release/2025/07/29/3123536/0/en/Hematologist-Dissatisfaction-with-Current-Warm-Autoimmune-Hemolytic-Anemia-w-AIHA-Treatment-Spurs-Interest-in-Late-Stage-Pipeline-According-to-Spherix-Global-Insights.html,"Hematologist Dissatisfaction with Current Warm Autoimmune Hemolytic Anemia (w-AIHA) Treatment Spurs Interest in Late-Stage Pipeline, According to Spherix Global Insights Hematologists report significant challenges in managing warm autoimmune hemolytic anemia (w-AIHA), with nearly half of patients not optimally treated. Physicians are interested in emerging pipeline therapies that could offer better treatment options."
2025-08-05 04:30:00+00:00,https://www.globenewswire.com/news-release/2025/08/05/3127014/0/en/Latest-Global-Paracetamol-Market-Size-Share-Worth-USD-1460-23-Million-by-2034-at-a-5-24-CAGR-Custom-Market-Insights-Analysis-Outlook-Leaders-Report-Trends-Forecast-Segmentation-Gro.html,"[Latest] Global Paracetamol Market Size/Share Worth USD 1460.23 Million by 2034 at a 5.24% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) The global paracetamol market is projected to grow from USD 876.48 Million in 2024 to USD 1460.23 Million by 2034, with a steady 5.24% CAGR, driven by increasing healthcare awareness and rising incidences of chronic conditions."
2025-08-05 17:00:00+00:00,https://www.globenewswire.com/news-release/2025/08/05/3127712/0/en/AAV-for-the-Hereditary-Retinal-Diseases-Clinical-Trial-Pipeline-Analysis-Demonstrates-70-Key-Companies-at-the-Horizon-Expected-to-Transform-the-Treatment-Paradigm-Assesses-DelveIns.html,"AAV for the Hereditary Retinal Diseases Clinical Trial Pipeline Analysis Demonstrates 70+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight A comprehensive analysis reveals over 70 companies developing AAV gene therapies for hereditary retinal diseases, offering potential transformative treatments for vision restoration through advanced gene therapy techniques."
2025-08-06 03:34:26+00:00,https://www.fool.com/data-news/2025/08/06/contineum-ctnm-q2-rd-jumps-78/?source=iedfolrf0000001,"Contineum (CTNM) Q2 R&D Jumps 78% Contineum Therapeutics reported a wider Q2 2025 net loss of $0.62 per share, driven by increased R&D expenses. The company continues developing treatments for pulmonary fibrosis, multiple sclerosis, and depression, with ongoing clinical trials for PIPE-791 and PIPE-307."
2025-08-07 04:34:27+00:00,https://www.fool.com/data-news/2025/08/07/protagonist-ptgx-q2-revenue-falls-26/?source=iedfolrf0000001,"Protagonist (PTGX) Q2 Revenue Falls 26% Protagonist Therapeutics reported Q2 2025 financial results, highlighting progress in clinical pipeline with rusfertide and icotrokinra drug candidates, while experiencing lower-than-expected revenue but maintaining strong cash reserves through 2028."
2025-08-07 22:23:53+00:00,https://www.fool.com/data-news/2025/08/07/rxsight-rxst-q2-loss-beats-estimates/?source=iedfolrf0000001,"RxSight (RXST) Q2 Loss Beats Estimates RxSight reported Q2 2025 financial results with mixed performance, experiencing a 4% revenue decline but improving gross margins and growing Light Adjustable Lens procedure volume by 13%."
2025-08-08 08:49:00+00:00,https://www.globenewswire.com/news-release/2025/08/08/3129963/28124/en/Spinal-Fusion-Devices-Market-Outlook-Report-2025-2029-Revenues-to-Grow-by-2-9-Billion-Driven-by-Rising-Spinal-Disorders-Technological-Advances-and-Increasing-Device-Launches.html,"Spinal Fusion Devices Market Outlook Report 2025-2029: Revenues to Grow by $2.9 Billion Driven by Rising Spinal Disorders, Technological Advances, and Increasing Device Launches The spinal fusion devices market is projected to grow by $2.9 billion from 2024 to 2029, with a 5.1% CAGR, driven by rising spinal disorders, technological advances, and increasing device launches."
2025-08-08 13:05:00+00:00,https://www.benzinga.com/pressreleases/25/08/n46997451/oncolytics-biotech-reports-second-quarter-financial-results-and-details-clinical-program-plans-for,"Oncolytics BiotechÂ® Reports Second Quarter Financial Results and Details Clinical Program Plans for Pelareorep Oncolytics Biotech reported Q2 2025 financial results, highlighting promising clinical data for pelareorep in pancreatic cancer and plans to pursue a registration-enabling pivotal study with potential FDA approval."
2025-08-09 22:14:00+00:00,https://www.fool.com/investing/2025/08/09/5-dividend-stocks-to-hold-for-the-next-5-years/?source=iedfolrf0000001,"5 Dividend Stocks to Hold for the Next 5 Years The article highlights five high-quality dividend stocks with consistent dividend growth and strong financial profiles, including companies from renewable energy, real estate, healthcare, consumer goods, and energy sectors."
2025-08-11 13:53:39+00:00,https://www.benzinga.com/news/health-care/25/08/47031295/novartis-investigational-drug-aces-two-pivotal-trials-for-chronic-disease-impacting-tears-saliva,"Novartis' Investigational Drug Aces Two Pivotal Trials For Chronic Disease Impacting Tears, Saliva Novartis reported successful Phase 3 trials for ianalumab, an investigational drug targeting SjÃ¶gren's disease, demonstrating statistically significant improvements in disease activity and a favorable safety profile."
2025-08-11 16:21:00+00:00,https://www.investing.com/analysis/3-big-dividend-plays-with-strong-earnings-to-back-them-200665112,"3 Big Dividend Plays With Strong Earnings to Back Them The article highlights three dividend-paying stocks with strong recent earnings: Waste Management, Eversource Energy, and Johnson & Johnson, demonstrating their potential for consistent dividend payouts and financial stability."
2025-08-13 02:29:33+00:00,https://www.fool.com/data-news/2025/08/13/vicarious-surgical-narrows-loss-in-q2/?source=iedfolrf0000001,"Vicarious Surgical Narrows Loss in Q2 Vicarious Surgical reported a narrower Q2 2025 non-GAAP loss of $2.23 per share, beating analyst estimates. The company remains pre-commercial, with no revenue and continued focus on securing FDA approval for its robotic surgical system."
2025-08-13 04:30:00+00:00,https://www.globenewswire.com/news-release/2025/08/13/3132275/0/en/Latest-Global-Canine-Orthopedics-Market-Size-Share-Worth-USD-945-2-Million-by-2034-at-a-8-6-CAGR-Custom-Market-Insights-Analysis-Outlook-Leaders-Report-Trends-Forecast-Segmentation.html,"[Latest] Global Canine Orthopedics Market Size/Share Worth USD 945.2 Million by 2034 at a 8.6% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) The global canine orthopedics market is projected to grow from USD 420.2 Million in 2024 to USD 945.2 Million by 2034, with an 8.6% CAGR, driven by increased pet healthcare awareness and advanced surgical technologies."
2025-08-13 10:05:00+00:00,https://www.fool.com/investing/2025/08/13/if-in-20s-consider-buying-healthcare-stock/?source=iedfolrf0000001,"If You're In Your 20's, Consider Buying These 3 Healthcare Stocks The article discusses three healthcare industry leaders - Medtronic, Johnson & Johnson, and Merck - as potential long-term investment opportunities for young investors, highlighting their ability to survive market challenges and provide consistent dividends."
2025-08-14 12:31:10+00:00,https://www.fool.com/data-news/2025/08/14/meiragtx-sales-jump-1133-percent/?source=iedfolrf0000001,"MeiraGTx Sales Jump 1,133 Percent MeiraGTx reported Q2 2025 results with significant revenue growth but missed analyst estimates. The company advanced several gene therapy programs, secured key partnerships, and maintained strong manufacturing capabilities despite ongoing financial challenges."
2025-08-14 15:03:00+00:00,https://www.investing.com/analysis/3-megacaps-that-outperformed-expectations-this-earnings-season-200665312,"3 Mega-Caps That Outperformed Expectations This Earnings Season During the Q2 2025 earnings season, three mega-cap companies demonstrated strong financial performance, beating market expectations and contributing to the ongoing bull market trend."
2025-08-16 14:30:00+00:00,https://www.fool.com/investing/2025/08/16/these-are-the-smartest-dividend-stocks-today/?source=iedfolrf0000001,"These Are the 3 Smartest Dividend Stocks Today The article highlights three dividend stocks - Coca-Cola, Realty Income, and Johnson & Johnson - that offer consistent dividend payouts and stability across economic cycles, making them attractive long-term investment options."
2025-08-17 23:23:00+00:00,https://www.fool.com/investing/2025/08/17/massive-headwinds-on-horizon-for-pharmaceutical-st/?source=iedfolrf0000001,"Massive Headwinds Are on the Horizon for Pharmaceutical Stocks, but Here Are 2 That Could Weather the Storm Two pharmaceutical companies, Johnson & Johnson and Novartis, are facing patent cliff challenges but demonstrate resilience through diversified product portfolios, innovative pipelines, and consistent dividend growth."
2025-08-19 17:54:00+00:00,https://www.globenewswire.com/news-release/2025/08/19/3135965/0/en/Global-Tissue-Engineering-and-Regeneration-Market-Set-to-Surge-at-12-8-CAGR-Through-2030.html,"Global Tissue Engineering and Regeneration Market Set to Surge at 12.8% CAGR Through 2030 The global tissue engineering and regeneration market is projected to grow from $5.4 billion in 2025 to $9.8 billion by 2030, driven by rising demand for regenerative medicine, increased research, and venture capital funding."
2025-08-21 08:38:00+00:00,https://www.globenewswire.com/news-release/2025/08/21/3136929/28124/en/Understanding-the-Nanomedicine-Landscape-Key-Players-and-Emerging-Trends.html,"Understanding the Nanomedicine Landscape: Key Players and Emerging Trends Nanomedicine is an emerging field combining nanotechnology with therapeutic molecules to enable targeted drug delivery, imaging, and diagnostics, offering more precise disease treatment approaches."
2025-08-22 12:00:00+00:00,https://www.globenewswire.com/news-release/2025/08/22/3137789/0/en/Global-Surgical-Sutures-Market-Poised-to-Reach-USD-6-65-Billion-by-2030-MarketsandMarkets.html,"Global Surgical Sutures Market Poised to Reach USD 6.65 Billion by 2030 | MarketsandMarketsâ„¢ The global surgical sutures market is projected to grow from $4.84 billion in 2025 to $6.65 billion by 2030, driven by increasing surgical procedures, technological advancements, and expanding healthcare access in emerging economies."
2025-08-25 08:04:00+00:00,https://www.fool.com/investing/2025/08/25/got-500-3-dividend-stocks-to-buy-and-hold-forever/?source=iedfolrf0000001,"Got $500? 3 Dividend Stocks to Buy and Hold Forever The article discusses three healthcare dividend stocks - Johnson & Johnson, Medtronic, and Omega Healthcare Investors - that offer attractive investment opportunities for income-focused investors seeking stable and potentially growing dividend returns."
2025-08-25 09:11:00+00:00,https://www.fool.com/investing/2025/08/25/should-you-buy-intuitive-surgical-stock-today-or-w/?source=iedfolrf0000001,"Should You Buy Intuitive Surgical Stock Today, or Wait for a Better Price? Intuitive Surgical, a medical device specialist in robotic surgery, shows strong financial performance and long-term growth potential despite facing competition and trade challenges. The company's da Vinci system remains a market leader with significant room for expansion in robotic-assisted surgical procedures."
2025-08-26 14:07:00+00:00,https://www.investing.com/analysis/as-the-market-rotates-this-healthcare-etf-is-leading-the-way-200665916,"As the Market Rotates, This Healthcare ETF Is Leading the Way The healthcare sector is experiencing a market rotation, with defensive stocks showing strength as tech stocks sell off. The iShares U.S. Healthcare ETF (IYH) is leading the way, offering broad exposure to beaten-down healthcare stocks with potential recovery."
2025-08-27 08:50:00+00:00,https://www.globenewswire.com/news-release/2025/08/27/3139790/28124/en/Chronic-Inducible-Urticaria-CIndU-Market-Research-Report-2025-2035-Competitive-Analysis-of-AstraZeneca-Celldex-Therapeutics-J-J-Merck-Novartis-Pfizer-Regeneron-Pharma-Sanofi-Sun-Ph.html,"Chronic Inducible Urticaria (CIndU) Market Research Report 2025-2035 | Competitive Analysis of AstraZeneca, Celldex Therapeutics, J&J, Merck, Novartis, Pfizer, Regeneron Pharma, Sanofi, Sun Pharma The global CIndU market is experiencing significant growth driven by advancements in diagnostic tools, biologic therapies, and increasing awareness of immune mechanisms, with emerging personalized medicine approaches promising improved patient outcomes."
2025-08-27 12:00:00+00:00,https://www.globenewswire.com/news-release/2025/08/27/3139928/0/en/Maxion-Therapeutics-Strengthens-Board-with-Appointment-of-Dr-Santiago-Arroyo-as-a-Non-Executive-Director.html,"Maxion Therapeutics Strengthens Board with Appointment of Dr. Santiago Arroyo as a Non-Executive Director Maxion Therapeutics appointed Dr. Santiago Arroyo as a Non-Executive Director, bringing extensive clinical development expertise from roles at multiple pharmaceutical and biotech companies."
2025-08-27 17:00:00+00:00,https://www.globenewswire.com/news-release/2025/08/27/3140258/0/en/Global-Pharmaceuticals-Market-to-Register-Immense-Growth-at-a-CAGR-of-7-by-2032-DelveInsight.html,"Global Pharmaceuticals Market to Register Immense Growth at a CAGR of ~7% by 2032 | DelveInsight The global pharmaceutical market is projected to grow from USD 1.4 billion in 2024 to USD 2.4 billion by 2032, driven by rising chronic disease prevalence, biotechnology advancements, and increasing healthcare expenditure. North America is expected to lead market growth."
2025-08-29 13:00:00+00:00,https://www.globenewswire.com/news-release/2025/08/29/3141500/0/en/SGLT2-Inhibitors-Market-to-Hit-USD-29-73-Billion-by-2032-Driven-by-Expanding-Diabetes-Management-and-Cardiovascular-Benefits-SNS-Insider.html,"SGLT2 Inhibitors Market to Hit USD 29.73 Billion by 2032, Driven by Expanding Diabetes Management and Cardiovascular Benefits â€“ SNS Insider The global SGLT2 Inhibitors Market is projected to grow from USD 16.90 billion in 2024 to USD 29.73 billion by 2032, driven by increasing diabetes management needs, cardiovascular benefits, and expanding clinical guidelines."
2025-08-29 15:00:00+00:00,https://www.globenewswire.com/news-release/2025/08/29/3141644/0/en/Dermatology-Market-to-Worth-USD-2-75-Billion-Size-by-2034.html,"Dermatology Market to Worth USD 2.75 Billion Size by 2034 The global dermatology market is expected to expand from USD 1.50 billion in 2025 to USD 2.75 billion by 2034, with a 6.94% CAGR. Key growth drivers include rising disposable incomes, increasing demand for cosmetic procedures, and advancements in skin treatment technologies."
2025-08-31 18:10:00+00:00,https://www.fool.com/investing/2025/08/31/these-4-dividend-stocks-are-money-printing-machine/?source=iedfolrf0000001,"These 4 Dividend Stocks Are Money-Printing Machines Four major companies demonstrate exceptional cash generation capabilities, consistently increasing dividends and returning value to shareholders through strategic financial management."
2025-09-01 14:00:00+00:00,https://www.globenewswire.com/news-release/2025/09/01/3142183/0/en/Acne-Medicine-Market-Size-Projected-to-Reach-USD-23-33-Billion-by-2034.html,"Acne Medicine Market Size Projected to Reach USD 23.33 Billion by 2034 The global acne medication market is expected to grow from USD 14.86 billion in 2025 to USD 23.33 billion by 2034, with a 5.14% CAGR. North America dominates the market, driven by high acne prevalence, innovative treatments, and strong pharmaceutical presence."
2025-09-02 13:00:00+00:00,https://www.globenewswire.com/news-release/2025/09/02/3142731/0/en/Grand-River-Aseptic-Manufacturing-GRAM-Appoints-Denis-Johnson-as-Chief-Executive-Officer.html,"Grand River Aseptic Manufacturing (GRAM) Appoints Denis Johnson as Chief Executive Officer Grand River Aseptic Manufacturing (GRAM) announced Denis Johnson's promotion to CEO, effective September 1, 2025, succeeding Derek Hennecke. Johnson brings extensive life sciences leadership experience and will drive strategic expansion and operational excellence."
2025-09-02 13:37:00+00:00,https://www.investing.com/analysis/healthcare-valuations-near-multiyear-lows-suggest-riskreward-asymmetry-200666254,"Healthcare Valuations Near Multi-Year Lows Suggest Riskâ€“Reward Asymmetry The healthcare sector is experiencing low valuations and potential for a quiet rebound, with improving technical indicators and significant institutional investment despite ongoing political and economic challenges."
2025-09-03 15:00:00+00:00,https://www.globenewswire.com/news-release/2025/09/03/3143841/0/en/Multiple-Myeloma-Market-Size-Projected-USD-49-89-Billion-by-2034.html,"Multiple Myeloma Market Size Projected USD 49.89 Billion by 2034 The global multiple myeloma market is expected to expand from $27.75 billion in 2024 to $49.89 billion by 2034, driven by advances in immunotherapies, diagnostic tools, and personalized treatment approaches."
2025-09-04 08:09:00+00:00,https://www.fool.com/investing/2025/09/04/could-these-3-dividend-kings-be-worth-1-trillion-i/?source=iedfolrf0000001,"Could These 3 Dividend Kings Be Worth $1 Trillion in 10 Years? Three major healthcare companies - AbbVie, Johnson & Johnson, and Abbott Laboratories - are analyzed for their potential to reach a $1 trillion market valuation within the next decade, with each company having unique strengths and growth opportunities."
2025-09-04 14:00:00+00:00,https://www.globenewswire.com/news-release/2025/09/04/3144696/28124/en/Software-Automation-in-Research-and-Development-R-D-Clinical-Trials-Training-Course-Harnessing-Automation-Technology-to-Deliver-Faster-Cost-Effective-Outcomes-Oct-1-2025.html,"Software Automation in Research and Development (R&D) Clinical Trials Training Course | Harnessing Automation Technology to Deliver Faster, Cost-Effective Outcomes (Oct 1, 2025) A training course focusing on software automation in clinical trials, highlighting technological advancements that can improve efficiency, patient recruitment, and trial management through digital solutions."
2025-09-04 17:00:00+00:00,https://www.globenewswire.com/news-release/2025/09/04/3144857/0/en/Global-Colorectal-Surgical-Devices-Market-to-Advance-at-Moderate-CAGR-of-8-by-2032-DelveInsight.html,"Global Colorectal Surgical Devices Market to Advance at Moderate CAGR of ~8% by 2032 | DelveInsight The colorectal surgical devices market is expected to grow at an 8% CAGR from 2025-2032, driven by rising colorectal cancer incidence, technological advancements in minimally invasive surgical techniques, and expanding screening programs."
2025-09-06 07:10:00+00:00,https://www.globenewswire.com/news-release/2025/09/06/3145593/0/en/RYBREVANT-amivantamab-plus-LAZCLUZE-lazertinib-reduces-acquired-resistance-versus-osimertinib-in-first-line-EGFR-mutated-advanced-non-small-cell-lung-cancer.html,RYBREVANTÂ®â–¼ (amivantamab) plus LAZCLUZEÂ®â–¼ (lazertinib) reduces acquired resistance versus osimertinib in first-line EGFR-mutated advanced non-small cell lung cancer New data from the Phase 3 MARIPOSA study shows that amivantamab plus lazertinib significantly reduces EGFR and MET resistance mutations compared to osimertinib monotherapy in first-line advanced non-small cell lung cancer treatment.
2025-09-07 07:28:00+00:00,https://www.globenewswire.com/news-release/2025/09/07/3145711/0/en/Data-published-in-The-New-England-Journal-of-Medicine-demonstrate-RYBREVANT-amivantamab-plus-LAZCLUZE-lazertinib-could-re-set-survival-expectations-in-first-line-EGFR-mutated-advan.html,"Data published in The New England Journal of Medicine demonstrate RYBREVANTÂ®â–¼(amivantamab) plus LAZCLUZEÂ®â–¼ (lazertinib) could re-set survival expectations in first-line EGFR-mutated advanced lung cancer A Phase 3 MARIPOSA study published in The New England Journal of Medicine shows that amivantamab plus lazertinib combination therapy significantly improves overall survival for patients with EGFR-mutated advanced non-small cell lung cancer, potentially extending median survival beyond four years compared to osimertinib monotherapy."
2025-09-09 12:00:00+00:00,https://www.globenewswire.com/news-release/2025/09/09/3146807/0/en/Numab-Therapeutics-Announces-Leadership-Transition-and-Appoints-Angehrn-Pavik-as-Chief-Executive-Officer.html,"Numab Therapeutics Announces Leadership Transition and Appoints Angehrn Pavik as Chief Executive Officer Numab Therapeutics has appointed Barbara Angehrn Pavik as new CEO, replacing co-founder David Urech, who will remain on the Board of Directors. Angehrn Pavik brings over two decades of biopharma experience and previously led Asceneuron and served at Vifor Pharma."
2025-09-10 10:23:00+00:00,https://www.fool.com/investing/2025/09/10/why-this-dividend-etf-is-perfectly-balanced-for/?source=iedfolrf0000001,"Why This Dividend ETF is Perfectly Balanced for Yield and Growth The article analyzes the iShares Core High Dividend ETF (HDV) as a balanced dividend investment option, highlighting its low expense ratio, solid dividend yield, and diversified portfolio of blue-chip stocks across multiple sectors."
2025-09-10 11:00:00+00:00,https://www.globenewswire.com/news-release/2025/09/10/3147622/0/en/Bariatric-Surgery-Market-to-Reach-USD-3-34-Billion-by-2032-Fueled-by-Rising-Obesity-Rates-and-Advances-in-Minimally-Invasive-Procedures-SNS-Insider.html,"Bariatric Surgery Market to Reach USD 3.34 Billion by 2032, Fueled by Rising Obesity Rates and Advances in Minimally Invasive Procedures | SNS Insider The global Bariatric Surgery Market is projected to grow from USD 1.70 billion in 2023 to USD 3.34 billion by 2032, driven by rising obesity rates and technological advancements in minimally invasive surgical techniques."
2025-09-12 09:10:00+00:00,https://www.fool.com/investing/2025/09/12/vanguard-etf-yield-more-sp-500-fee-vym/?source=iedfolrf0000001,"Meet the Vanguard ETF That Yields More Than Twice the S&P 500 Average and Has Minimal Fees The Vanguard High Dividend Yield ETF offers investors a high-yield dividend strategy with low fees, holding 580 stocks and providing a 2.5% dividend yield, which is more than double the S&P 500 average."
2025-09-15 09:19:00+00:00,https://www.fool.com/investing/2025/09/15/if-you-invested-1000-in-johnson-johnson-stock-5-yr/?source=iedfolrf0000001,"If You'd Invested $1,000 in Johnson & Johnson (JNJ) Stock 5 Years Ago, Here's How Much You'd Have Today A $1,000 investment in Johnson & Johnson 5 years ago would be worth $1,359, underperforming the S&P 500. Despite modest growth, the company shows promise with consistent dividend increases and strong quarterly earnings."
2025-09-16 16:22:54+00:00,https://www.benzinga.com/markets/large-cap/25/09/47697142/eli-lilly-to-invest-5-billion-in-new-virginia-manufacturing-facility-to-support-cancer-drugs-ma,"Eli Lilly To Invest $5 Billion In New Virginia Manufacturing Facility To Support Cancer Drugs Manufacturing Eli Lilly plans to build a $5 billion manufacturing facility in Virginia focused on producing cancer drugs using advanced AI and machine learning technologies, creating over 650 new jobs and supporting its oncology portfolio."
2025-09-17 19:15:33+00:00,https://www.benzinga.com/markets/large-cap/25/09/47725129/johnson-johnson-protagonist-study-shows-superior-skin-clearance-in-psoriasis-trials,"Johnson & Johnson, Protagonist Study Shows Superior Skin Clearance In Psoriasis Trials Johnson & Johnson and Protagonist Therapeutics released Phase 3 study results for icotrokinra, showing superior skin clearance in psoriasis treatment compared to placebo and competitor drugs, with sustained effectiveness and favorable safety profile."
2025-09-18 15:00:00+00:00,https://www.globenewswire.com/news-release/2025/09/18/3152612/0/en/Topical-Drugs-CDMO-Market-Size-to-Expand-USD-136-71-Billion-by-2034.html,"Topical Drugs CDMO Market Size to Expand USD 136.71 Billion by 2034 The global topical drugs Contract Development and Manufacturing Organization (CDMO) market is projected to grow from $46.32 billion in 2024 to $136.71 billion by 2034, with a CAGR of 11.43%. Key growth drivers include increasing demand for non-invasive therapies, advancements in drug delivery technologies, and expanding pharmaceutical outsourcing."
2025-09-19 17:54:48+00:00,https://www.benzinga.com/markets/large-cap/25/09/47770012/johnson-johnsons-tecvayli-darzalex-combo-shows-100-response-in-newly-diagnosed-myeloma-patients,"Johnson & Johnson's Tecvayli-Darzalex Combo Shows 100% Response In Newly Diagnosed Myeloma Patients Johnson & Johnson reported promising clinical trial results for a new multiple myeloma treatment combination, with 100% patient response and 85.7% achieving complete response in newly diagnosed patients."
2025-09-22 13:22:00+00:00,https://www.investing.com/analysis/kenvue-stock-pressure-highlights-litigation-and-regulatory-risk-premium-200667286,"Kenvue Stock Pressure Highlights Litigation and Regulatory Risk Premium Kenvue's stock dropped 6.05% in premarket trading after the Trump administration plans to announce a potential link between Tylenol use during pregnancy and autism risk, reigniting concerns about the company's flagship product."
2025-09-24 14:00:00+00:00,https://www.globenewswire.com/news-release/2025/09/24/3155574/0/nl/Financi%C3%A8re-de-Tubize-versterkt-haar-expertise-in-de-biopharmasector-door-de-benoeming-van-2-nieuwe-bestuurders.html,"FinanciÃ¨re de Tubize versterkt haar expertise in de biopharmasector door de benoeming van 2 nieuwe bestuurders FinanciÃ¨re de Tubize appointed two new board directors, Iris LÃ¶w-Friedrich and Carinne Brouillon, to enhance its biopharmaceutical expertise and support UCB's strategic development."
2025-09-24 14:00:00+00:00,https://www.globenewswire.com/news-release/2025/09/24/3155574/0/fr/La-Financi%C3%A8re-de-Tubize-renforce-son-expertise-dans-le-domaine-biopharma-en-nommant-2-nouvelles-administratrices.html,"La FinanciÃ¨re de Tubize renforce son expertise dans le domaine biopharma en nommant 2 nouvelles administratrices La FinanciÃ¨re de Tubize has appointed two new board members, Iris LÃ¶w-Friedrich and Carinne Brouillon, to enhance its biopharma expertise and support UCB's strategic development. Cyril Janssen was also named Vice-President to manage shareholder relations."
2025-09-24 14:00:00+00:00,https://www.globenewswire.com/news-release/2025/09/24/3155574/0/en/Financi%C3%A8re-de-Tubize-strengthens-its-expertise-in-the-biopharma-field-by-appointing-2-new-directors.html,"FinanciÃ¨re de Tubize strengthens its expertise in the biopharma field by appointing 2 new directors UCB's Board of Directors appointed two new directors, Iris LÃ¶w-Friedrich and Carinne Brouillon, to enhance biopharma expertise. Bruno Holthof highlighted the strategic importance of these appointments, and Cyril Janssen was named Vice-President to manage family shareholder relations."
2025-09-25 08:44:00+00:00,https://www.globenewswire.com/news-release/2025/09/25/3156044/28124/en/Craniomaxillofacial-Devices-Market-Industry-Trends-Key-Growth-Drivers-Challenges-Future-Opportunities-and-Regulatory-Landscape-2025-2034.html,"Craniomaxillofacial Devices Market Industry Trends, Key Growth Drivers, Challenges, Future Opportunities, and Regulatory Landscape 2025-2034 The global craniomaxillofacial devices market is projected to grow from $1.8 billion in 2024 to $3.9 billion by 2034, driven by increased facial injuries, technological advancements, and minimally invasive surgical techniques."
2025-09-26 14:21:00+00:00,https://www.investing.com/analysis/jabils-aidriven-boom-has-begun-news-highs-are-coming-200667580,"Jabils AI-Driven Boom Has Begun: News Highs are Coming Jabil demonstrates strong Q4 2025 performance with 18.5% revenue growth, benefiting from AI and tech sector strengths in capital equipment, data center, and networking markets. The company shows robust financial health with favorable guidance and potential for significant stock price appreciation."
2025-09-28 12:10:00+00:00,https://www.fool.com/investing/2025/09/28/is-palantir-technologies-stock-a-buy-now/?source=iedfolrf0000001,"Is Palantir Technologies Stock a Buy Now? Palantir Technologies is experiencing significant growth with strong government and commercial revenue, but faces skepticism due to its high valuation metrics. The company's Artificial Intelligence Platform (AIP) is driving expansion, with 50% projected quarterly growth and impressive deal closures."
2025-09-28 22:15:00+00:00,https://www.fool.com/investing/2025/09/28/why-johnson-could-be-the-ultimate-dividend-stock/?source=iedfolrf0000001,"Why Johnson & Johnson Could Be the Ultimate Dividend King Johnson & Johnson (J&J) continues its impressive dividend track record, having increased dividends for 63 consecutive years. After spinning off its consumer health business, J&J is now a focused healthcare company with strong pharmaceutical and medical technology segments, generating significant revenue and investing heavily in R&D."
2025-09-29 22:30:00+00:00,https://www.globenewswire.com/news-release/2025/09/29/3158214/0/en/NANOBIOTIX-Announces-Updated-Phase-1-Results-Continuing-to-Support-JNJ-1900-NBTXR3-Plus-Anti-PD-1-as-a-Potential-New-1L-or-2L-Option-in-Anti-PD-1-Na%C3%AFve-or-Resistant-R-M-HNSCC.html,"NANOBIOTIX Announces Updated Phase 1 Results Continuing to Support JNJ-1900 (NBTXR3) Plus Anti-PD-1 as a Potential New 1L or 2L+ Option in Anti-PD-1 NaÃ¯ve or Resistant R/M-HNSCC A Phase 1 study evaluated JNJ-1900 (NBTXR3), a nanoparticle treatment activated by radiation therapy, in combination with anti-PD-1 immunotherapy for recurrent/metastatic head and neck squamous cell carcinoma. Results showed promising disease control rates and potential for overcoming anti-PD-1 resistance."
2025-09-29 22:30:00+00:00,https://www.globenewswire.com/news-release/2025/09/29/3158214/0/fr/NANOBIOTIX-annonce-de-nouveaux-r%C3%A9sultats-de-Phase-1-qui-continuent-de-confirmer-le-potentiel-de-JNJ-1900-NBTXR3-avec-un-anti-PD-1-en-tant-que-potentielle-nouvelle-option-th%C3%A9rapeuti.html,"NANOBIOTIX annonce de nouveaux rÃ©sultats de Phase 1 qui continuent de confirmer le potentiel de JNJ-1900 (NBTXR3), avec un anti-PD-1, en tant que potentielle nouvelle option thÃ©rapeutique de premiÃ¨re ou deuxiÃ¨me ligne ou plus dans le CETEC R/M naÃ¯f ou rÃ©sistant aux anti-PD-1 NANOBIOTIX reported promising Phase 1 clinical trial results for JNJ-1900 (NBTXR3), a nanoparticle-based cancer treatment, showing favorable safety profile and potential efficacy in treating recurrent/metastatic head and neck squamous cell carcinoma patients, both naive and resistant to anti-PD-1 treatments."
2025-09-30 22:07:33+00:00,https://www.fool.com/data-news/2025/09/30/stock-market-today-pfizer-rallies-on-trump-drug-pr/?source=iedfolrf0000001,"Stock Market Today: Pfizer Rallies on Trump Drug Pricing Deal and U.S. Investment Pledge Pfizer surged after striking a landmark agreement with the Trump administration to lower drug prices and expand U.S. production, securing a three-year tariff exemption and committing to $70 billion in U.S. manufacturing investments."
2025-10-02 17:00:00+00:00,https://www.globenewswire.com/news-release/2025/10/02/3160610/0/en/Global-General-Surgery-Devices-Market-to-Register-Sustainable-Growth-at-a-CAGR-of-6-by-2032-DelveInsight.html,"Global General Surgery Devices Market to Register Sustainable Growth at a CAGR of ~6% by 2032 | DelveInsight The global general surgery devices market is projected to grow from $22 million in 2024 to $35 million by 2032, driven by increasing surgical procedures, technological advancements, and rising demand for minimally invasive surgeries."
2025-10-03 16:51:00+00:00,https://www.globenewswire.com/news-release/2025/10/03/3161132/28124/en/Eyewear-Worldwide-Industry-Competition-Analysis-and-Investment-Opportunities-to-2034.html,"Eyewear: Worldwide Industry Competition Analysis and Investment Opportunities to 2034 The global eyewear market is projected to grow from $136.66 billion in 2024 to $185.45 billion by 2034, driven by increasing visual impairments, aging populations, and technological advancements in lens and retail technologies."
2025-10-06 17:00:00+00:00,https://www.globenewswire.com/news-release/2025/10/06/3161983/0/en/Diffuse-Cutaneous-Systemic-Sclerosis-Market-Forecast-Opportunities-and-Growth-Trends-Upto-2034-DelveInsight.html,"Diffuse Cutaneous Systemic Sclerosis Market Forecast: Opportunities and Growth Trends Upto 2034 | DelveInsight The diffuse cutaneous systemic sclerosis (dcSSc) market is evolving towards targeted therapies addressing fibrosis and immune modulation, with promising drug candidates from multiple pharmaceutical companies targeting various pathogenic pathways."
2025-10-07 07:26:00+00:00,https://www.fool.com/investing/2025/10/07/1-reason-im-watching-hot-ticker-stock-in-2026/?source=iedfolrf0000001,"1 Reason I'm Watching Intuitive Surgical Stock in 2026 Intuitive Surgical is launching its da Vinci 5 surgical robotics system with a promising force feedback feature, potentially strengthening its market position despite increasing competition from major medical device companies."
2025-10-07 17:50:00+00:00,https://www.globenewswire.com/news-release/2025/10/07/3162868/0/en/Viplink-Launches-CPM-Guaranteed-Influencer-Campaigns-to-Help-Brands-Control-Rising-Marketing-Costs.html,"Viplink Launches CPM-Guaranteed Influencer Campaigns to Help Brands Control Rising Marketing Costs Viplink introduces a new influencer marketing service offering predictable campaign results and cost efficiency, targeting brands seeking transparent ROI in the growing creator economy."
2025-10-08 15:00:00+00:00,https://www.globenewswire.com/news-release/2025/10/08/3163530/0/en/Multiple-Myeloma-CAR-T-Market-Set-for-Rapid-Growth-Driven-by-BCMA-Targeted-Therapies-and-Innovative-Advances.html,"Multiple Myeloma CAR-T Market Set for Rapid Growth Driven by BCMA-Targeted Therapies and Innovative Advances The global multiple myeloma CAR-T market is experiencing rapid growth, with projected revenues expected to reach hundreds of millions between 2025 and 2034. The market is driven by BCMA-targeted therapies, technological innovations, and increasing demand for personalized cancer treatments."
2025-10-08 17:00:00+00:00,https://www.globenewswire.com/news-release/2025/10/08/3163647/0/en/CAR-T-Cell-Therapy-for-Multiple-Myeloma-Market-to-Witness-Upsurge-in-Growth-by-2034-Owing-to-the-Launch-of-Emerging-Therapies-DelveInsight.html,"CAR T-Cell Therapy for Multiple Myeloma Market to Witness Upsurge in Growth by 2034 Owing to the Launch of Emerging Therapies | DelveInsight The CAR T-cell therapy market for multiple myeloma is expected to grow significantly by 2034, driven by extensive R&D activities, emerging therapies targeting BCMA, and increasing multiple myeloma incidence rates."
2025-10-10 08:19:00+00:00,https://www.fool.com/investing/2025/10/10/is-this-beaten-down-dividend-king-a-buy/?source=iedfolrf0000001,"Is This Beaten-Down Dividend King a Buy? Kenvue, a recently spun-off consumer healthcare company from Johnson & Johnson, is experiencing declining sales, leadership changes, and potential market challenges, making its dividend status uncertain despite its Dividend King legacy."
2025-10-10 14:00:00+00:00,https://www.globenewswire.com/news-release/2025/10/10/3164931/0/en/Aesthetics-Market-to-Reach-USD-148-27-Billion-by-2033-Driven-by-Surge-in-Minimally-Invasive-Procedures-and-Global-Cosmetic-Innovation-SNS-Insider.html,"Aesthetics Market to Reach USD 148.27 Billion by 2033, Driven by Surge in Minimally Invasive Procedures and Global Cosmetic Innovation â€“ SNS Insider The global aesthetics market is projected to grow from USD 87.08 billion in 2025 to USD 148.27 billion by 2033, with a CAGR of 6.89%. The market is driven by minimally invasive procedures, technological innovation, and increasing consumer demand for aesthetic enhancements."
2025-10-10 17:06:05+00:00,https://www.benzinga.com/m-a/25/10/48155373/johnson-johnson-in-talks-to-acquire-protagonist-therapeutics-report,"Johnson & Johnson In Talks To Acquire Protagonist Therapeutics: Report Johnson & Johnson is reportedly in discussions to acquire Protagonist Therapeutics, potentially strengthening its immunology and oncology portfolio by gaining access to rusfertide, an experimental therapy for rare blood cancer."
2025-10-10 23:07:07+00:00,https://www.fool.com/investing/2025/10/10/why-protagonist-therapeutics-stock-skyrocketed-by/?source=iedfolrf0000001,"Why Protagonist Therapeutics Stock Skyrocketed by Almost 30% Today Clinical-stage biotech Protagonist Therapeutics saw its stock price jump 29.8% after The Wall Street Journal reported Johnson & Johnson is in discussions to acquire the company, based on their existing collaboration in drug development."
2025-10-12 19:14:54+00:00,https://www.fool.com/coverage/filings/2025/10/12/douglas-lane-adds-usd6-million-in-j-and-j-stock-ahead-of-earnings-and-possible-biotech-deal/?source=iedfolrf0000001,"Douglas Lane Adds $6 Million in J&J Stock Ahead of Earnings and Possible Biotech Deal Douglas Lane & Associates increased its Johnson & Johnson stake by 34,948 shares, worth approximately $6 million in Q3, bringing total holdings to 667,373 shares valued at $123.7 million. The investment comes ahead of J&J's earnings report and potential biotech acquisition of Protagonist Therapeutics."
2025-10-13 10:10:00+00:00,https://www.fool.com/investing/2025/10/13/drug-stocks-just-had-their-best-week-in-2-decades/?source=iedfolrf0000001,"Drug Stocks Just Had Their Best Week in 2 Decades. Should You Invest? Pharmaceutical stocks experienced significant gains after the Trump administration delayed potential drug import tariffs, with major drugmakers striking deals to invest in U.S. manufacturing and avoid potential 100% tariffs."
2025-10-13 14:30:41+00:00,https://www.benzinga.com/news/fda/25/10/48177054/fda-adds-new-warning-johnson-johnsons-cancer-cell-therapy-over-rare-immune-related-gut-inflammation,"FDA Adds New Warning For Johnson & Johnson's Cancer Cell Therapy The FDA updated safety labeling for Johnson & Johnson's Carvykti cancer cell therapy, adding a warning about immune effector cell-associated enterocolitis, a serious complication with potential fatal outcomes. Despite the warning, regulators affirmed the therapy's benefits continue to outweigh its risks."
2025-10-14 12:51:28+00:00,https://www.benzinga.com/markets/earnings/25/10/48196108/johnson-johnson-to-separate-orthopedics-business-boosts-annual-sales-outlook,"Johnson & Johnson To Separate Orthopedics Business, Boosts Annual Sales Outlook Johnson & Johnson reported strong Q3 2025 earnings, beating consensus estimates, and announced plans to separate its Orthopedics business into a standalone entity called DePuy Synthes within 18-24 months, targeting increased top-line growth and operating margins."
2025-10-15 08:47:00+00:00,https://www.globenewswire.com/news-release/2025/10/15/3166856/28124/en/Contact-Lenses-Market-Trends-Shares-Strategies-and-Growth-Analysis-Report-2025-2034-Featuring-Alcon-Vision-Bausch-Lomb-J-J-Vision-Care-CooperVision-Essilor-International-and-More.html,"Contact Lenses Market Trends, Shares, Strategies and Growth Analysis Report (2025-2034) Featuring Alcon Vision, Bausch & Lomb, J&J Vision Care, CooperVision, Essilor International and More Global contact lenses market projected to grow from $14.78 billion in 2024 to $29.35 billion by 2034, driven by technological innovations, rising vision health awareness, and integration of AR/VR technologies."
2025-10-15 09:20:00+00:00,https://www.fool.com/investing/2025/10/15/this-27-yielding-dividend-king-remains-one-of-the/?source=iedfolrf0000001,"This 2.7%-Yielding Dividend King Remains One of the Healthiest Income Stocks You Can Buy Johnson & Johnson demonstrated strong financial health in Q3, with 7% sales growth, $14.2 billion in free cash flow, and plans to separate its orthopedics business to focus on six priority growth areas. The company remains committed to dividend growth and oncology investments."
2025-10-15 17:03:00+00:00,https://www.fool.com/investing/2025/10/15/2-dividend-stocks-very-thankful-i-owned-this-year/?source=iedfolrf0000001,"2 Dividend Stocks I'm Very Thankful I Owned This Year Two tech and healthcare stocks, Meta Platforms and Johnson & Johnson, demonstrated strong market performance in 2025, with Meta leveraging AI advancements and Johnson & Johnson maintaining a stable dividend track record despite market challenges."
2025-10-16 13:09:59+00:00,https://www.benzinga.com/news/legal/25/10/48248432/johnson-johnson-reportedly-faces-major-uk-lawsuit-over-baby-powder-cancer-risks,"Johnson & Johnson Reportedly Faces Major UK Lawsuit Over Baby Powder Cancer Risks Johnson & Johnson faces a potential massive UK lawsuit involving 3,000 claimants alleging the company sold asbestos-contaminated baby powder, with estimated damages in hundreds of millions of pounds. This comes a week after a US jury ordered J&J to pay $966 million in a similar case."
2025-10-16 14:18:35+00:00,https://www.benzinga.com/news/legal/25/10/48251259/johnson-johnson-kenvue-named-in-first-ever-uk-legal-action-over-talc-cancer-claims,"Johnson & Johnson, Kenvue Named In First Ever UK Legal Action Over Talc Cancer Claims Thousands of UK claimants are suing Johnson & Johnson and Kenvue, alleging the companies sold asbestos-contaminated talcum powder that caused cancer, with the lawsuit claiming the companies concealed health risks for decades."
2025-10-16 17:37:03+00:00,https://www.benzinga.com/news/health-care/25/10/48258803/johnson-johnsons-multiple-myeloma-patients,"Johnson & Johnson Reports Strong Phase 3 Results For Multiple Myeloma Therapy Johnson & Johnson announced positive Phase 3 trial results for Tecvayli, a multiple myeloma therapy, showing significant improvements in progression-free and overall survival compared to standard treatments."
2025-10-16 18:08:00+00:00,https://www.investing.com/analysis/johnson--johnson-builds-momentum-as-margin-expansion-strategy-takes-hold-200668661,"Johnson & Johnson Builds Momentum as Margin Expansion Strategy Takes Hold Johnson & Johnson reported strong Q3 performance with 6.8% business growth, plans to spin off orthopedics unit, and continues to focus on higher-margin healthcare markets while maintaining solid financial health."
2025-10-16 22:06:06+00:00,https://www.fool.com/investing/2025/10/16/why-kenvue-stock-tumbled-by-13-on-thursday/?source=iedfolrf0000001,"Why Kenvue Stock Tumbled by 13% on Thursday Consumer healthcare company Kenvue experienced a significant stock sell-off after a group of approximately 3,000 claimants filed a lawsuit in the UK regarding its talc-based baby powder, alleging cancer-causing properties."
